Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the pro-inflammatory cytokines such as tumor necrosis factor-ce (TNF-ce) and interleukin-lj3 (IL-1)3), contribute to the pathogenesis of various allergic, inflammatory and autoimmune diseases. Consequently, multiple therapeutic approaches have been aimed at reducing the expression and/or activity of such pro-inflammatory cytokines. Examples of these include the use of IL-I receptor antagonists, TNF- ⁇ converting enzyme inhibitors, and inhibitors of certain enzymes that play a role in signal transduction pathways associated with inflammation, including responses to and expression of TNF-ce and lL-l ⁇ .
• TNF-ce tumor necrosis factor-ce
• IL-1 interleukin-lj3
• Immunomodulatory and inflammatory effects also play a role in cardiovascular conditions, such as atherogenesis and its associated cardiovascular risks, such as atherosclerosis, thrombosis, myocardial infarction, ischemic stroke, ischemic-reperfusion injury and peripheral vascular diseases.
• cardiovascular conditions such as atherosclerosis, thrombosis, myocardial infarction, ischemic stroke, ischemic-reperfusion injury and peripheral vascular diseases.
• inflammatory responses including those involving TNF-ce and IL- 1/3, play a role in the initiation, growth and disruption of atheroslerotic plaques.
• Treatments of such cardiovascular conditions typically address hypercholesterolemia, for example, by inhibiting the enzymes involved in cholesterol biosynthesis.
• Statins for example, inhibit 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthesis pathway.
• HMG-CoA 3-hydroxy-3-methylglutaryl CoA
• the present invention provides compounds and compositions that show MAP kinase inhibitory activity and/or HMG-CoA reductase inhibitory activity.
• Some embodiments are compounds comprising novel analogs of MAP kinase inhibitors.
• Some embodiments are compounds comprising novel analogs of HMG-CoA reductase inhibitors.
• Some embodiments are compounds comprising novel series of substituted imidazoles, substituted pyrazoles, or substituted pyrroles.
• Some embodiments are componds comprising novel series of substituted indoles, substituted pyridines, substituted pyrimidines, or substituted quinolines.
• Some embodiments are compounds comprising structures modified to favor and/or enforce a closed ring structure, e.g, a ⁇ -lactam or a des- oxo-structure. Some embodiments are combinations comprising two more compounds described herein and/or two or more forms of a compound described herein.
• the present invention provides methods of treating a MAP kinase- and/or an HMG-CoA reductase-related condition by administering an effective amount of a compound or combination of compounds to a subject, hi some embodiments, known inhibitors of HMG-CoA reductase are used to inhibit a MAP kinase, e.g., p38o; MAP kinase, in the treatment of a MAP kinase-related condition or in the treatment of both a MAP kinase- and an HMG-CoA reductase-related condition, hi other embodiments, novel compounds that inhibit both a MAP kinase and HMG-CoA reductase are superior to compounds that target a MAP kinase but not HMG-CoA reductase or to compounds that target HMG-CoA reductase and not MAP kinase, for example, in treating a MAP kina
• the present invention provides pharmaceutical compositions, formulations and modes of administering one or more compounds, e.g., compounds of the present invention, for use in methods of treating a MAP kinase-related and/or an HMG- CoA reeductase-related condition, including inflammatory conditions.
• a statin lactone can be formulated with a hydroxy acid form of the same or different statin, a pharmaceutically acceptable salt thereof, or with another active agent.
• a statin lactone can be formulated with a non- statin anti-inflammatory agent.
• Such combination formulations are administered orally or topically in preferred embodiments, e.g., in the treatment of inflammatory conditions.
• the present invention provides methods for the rational design of inhibitors of MAP kinase, HMG-CoA reductase, or both for use in the practice of the present invention.
• such methods involve designing a compound comprising a lipophilic moiety, e.g., a lipophilic MAP kinase inhibitor, or a moiety or analog thereof, or comprising a lipophilic moiety or analog of an HMG-CoA reductase inhibitor; testing the designed compound for MAP kinase and/or HMG-CoA reductase inhibitory activity; and using the compound to make a composition for inhibiting MAP kinase and/or HMG-CoA reductase, e.g., for use in the practice of the present invention, hi some embodiments, two or more designed compounds or forms thereof are used in preparing combination formulations, e.g., as described herein.
• the present invention provides compositions that show MAP kinase inhibitory and/or 3-hydroxy-3-methyl glutaryl-coenzyme A reductase (HMG-CoA reductase) inhibitory activity.
• Some embodiments are compositions comprising novel analogs of MAP kinase inhibitors.
• Some embodiments are compositions comprising novel analogs of HMG-CoA reductase inhibitors.
• Some embodiments are compositions comprising structures modified to favor and/or enforce a closed ring structure, e.g., a ⁇ - lactam or a des-oxo-structure.
• compositions comprising combinations of a lactone form of a "statin" inhibitor of HMG-CoA reductase with one or more additional pharmacologically active agents.
• Some embodiments are compositions comprising a statin lactone and the hydroxy acid form of a statin, or a pharmaceutically acceptable salt thereof.
• An embodiment of the invention includes compositions where the ratio of lactone statin to hydroxy acid statin is between about 99:1 and about 1:99.
• Preferred embodiments include a composition comprising an atorvastatin lactone and a composition comprising an atorvastatin hydroxy acid or a pitavastatin hydroxy acid.
• compositions comprising a statin lactone and a non-statin anti-inflammatory agent.
• An embodiment of the invention includes compositions where the ratio of lactone statin to non-statin anti-inflammatory agent is between about 99:1 and about 1:99.
• Preferred embodiments include compositions comprising an atorvastatin lactone and/or indomethacin.
• a composition comprising an atorvastatin lactone and indomethacin has a synergistic effect.
• the present invention provides methods of treating an inflammatory condition by administering an effective amount of a pharmaceutical composition, e.g., a composition of the present invention, to a subject.
• a pharmaceutical composition e.g., a composition of the present invention
• the invention provides methods which target both a MAP kinase, e.g., p38ce MAP kinase and HMG-CoA reductase for inhibition that are superior to methods that that target a MAP kinase but not HMG-CoA reductase or to methods that target HMG-CoA reductase and not MAP kinase, for example, in the treatment of a MAP kinase- and/or an HMG-CoA reductase-related condition.
• the present invention relates to the use, in the treatment of a MAP kinase-related conditions that are inflammatory diseases and disorders associated with inflammation, of pharmaceutical compositions comprising combinations of a lactone form of a "statin" inhibitor of the enzyme 3-hydroxy-3-methyl glutaryl-coenzyme A reductase (HMG-CoA reductase) with one or more additional pharmacologically active agents.
• a pharmaceutical composition comprising a combination of a statin lactone and a hydroxy acid statin salt, e.g., as a therapy to treat inflammatory diseases and disorders associated with inflammation, preferably vascular diseases and disorders.
• a pharmaceutical composition comprising a combination of a statin lactone and a hydroxy acid statin salt, e.g., as a topical therapy to treat inflammatory diseases and disorders of the skin.
• a pharmaceutical composition comprising a combination of a statin lactone and a non-statin anti-inflammatory agent, e.g., as a therapy to treat inflammatory diseases and disorders.
• a combination of a statin lactone and another active agent provides a synergistic effect in treating a MAP kinase- related condition, e.g., an inflammatory condition.
• One aspect of the present invention provides methods of inhibiting a MAP kinase comprising administering an effective amount of at least one compound comprising formula V: Formula V wherein R 1 is
• n O or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl
• R 4 is optionally substituted
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• n being 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl;
• R 4 is optionally substituted
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof, with the proviso that when R 4 Is the pyridinyl ring optionally substituted with one or more substituents selected from halogen atoms and hydroxyl, C 1-3 alkyl, C 1-3 alkoxy and trifluoromethyl groups, then the bridging group OfR 1 is -CH 2 -CH 2 -.
• Some embodiments provide a compound comprising fo ⁇ nula V:
• n being 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl;
• R 4 is optionally substituted and
• R- 5 is optionally substituted aryl or heteroaryl, or a salt thereof, with the proviso that when R 4 is the pyridinyl ring, said pyridinyl ring is substituted with one or more optionally substituted amino groups.
• n being 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyrimidinyl ring is optionally substituted; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• a compound comprising formula Vb is provided:
• n being 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyridinyl ring is optionally substituted, with the proviso that when the pyridinyl ring is unsubstituted or substituted with one or more substituents selected from halogen atoms and hydroxy!, C 1-3 alkyl, C 1-3 alkoxy and trifluoromethyl groups, then the bridging group OfR 1 is -CH 2 -CH 2 -; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• Another aspect of the present invention provides methods of inhibiting a MAP kinase comprising administering an effective amount of at least one compound comprising formula VI:
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl
• R 4 is optionally substituted and R 5 is optionally substituted aryl or heteroaryl, or a salt therof.
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl
• R 4 is optionally substituted
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof, with the proviso that when R 2 is an alkyl from 1-3 carbon atoms, trifluoromethyl, diakylamino where alkyl is 1-4 carbon atoms, pyrrolidino, piperidino, morpholino or piperazino, then R 4 is substituted.
• R 1 is an alkyl from 1-3 carbon atoms, trifluoromethyl, diakylamino where alkyl is 1-4 carbon atoms, pyrrolidino, piperidino, morpholino or piperazino
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; R 4 is substituted
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• n O or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl
• the pyrimidinyl ring is optionally substituted
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof
• R 2 is an alkyl from 1-3 carbon atoms, trifluoromethyl
• R 4 is substituted.
• n being 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyridinyl ring is optionally substituted; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof,with the proviso that when R 2 is an alkyl from 1-3 carbon atoms, trifluoromethyl, diakylamino in which alkyl is 1-4 carbon atoms, pyrrolidine, piperidino, morpholino or piperazino, then R 4 is substituted.
• Another aspect of the present invention provides methods of inhibiting a MAP kinase comprising administering an effective amount of at least one compound comprising formula VII
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; R 3 is any substituent; R 4 is optionally substituted
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• Another aspect of the present invention provides a compound comprising formula VII: Formula VII wherein R 1 is
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; R 3 is any substituent; R 4 is optionally substituted
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; R 3 is any substituent; R 4 is substituted
• R 4 is substituted with one or more optionally substituted amino groups or optionally substituted alkoxy groups; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• n being 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyridinyl ring is substituted; and R- 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• a compound comprising formula VIIb is provided:
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyrimidinyl ring is optionally substituted; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• the inhibited MAP kinase is p38 MAP kinase.
• the method further comprises inhibiting an HMG CoA reductase.
• the administering treats a MAP kinase-related condition.
• the administering treats a MAP kinase-related condition and an HMG CoA reductase-related condition.
• the administering treats an inflammatory condition.
• Still another aspect of the instant invention provides a pharmaceutical composition comprising an effective amount of at least one compound as recited above with a pharmaceutically acceptable carrier.
• Still other aspects of the instant invention provide methods of treating a condition in a subject in need thereof comprising administering to the subject an effective amount of at least one compound comprising formula V, VI and/or VII.
• Figure 1 illustrates some of the pathways involved in inflammatory signaling cascades and the interruption of certain of these pathways by a MAP kinase inhibitor.
• Figure 2a illustrates some of the pathways involved in cholesterol biosynthesis and some of the atherogenic mechanisms of hypercholesterolemia, as well as the interruption of certain of these pathways by an HMG-CoA reductase inhibitor.
• Figure 2b illustrates some of the pathways involved in processing amyloid precursor protein, the role played by cholesterol in such pathways, as well as the interruption of certain of these pathways by an HMG-CoA reductase inhibitor.
• Figure 3 illustrates the inter-conversion of a lactone (formula I) and acid forms (formulas IIa and lib) of a compound of the present invention
• Figure 3 a illustrates non- specific configurations at each of the two stereogenic centers of formulas I, Ha, and lib
• Figure 3b illustrates a preferred absolute configuration, designated (T, T).
• Figure 4 illustrates one or more examples of each of twelve classes (a-1) of inhibitors of p38 ⁇ MAP kinase.
• Figure 5 illustrates lactone derivatives of one example each of twelve classes (a-1) of inhibitors of p38a MAP kinase.
• Figure 6 illustrates an example of each of twelve classes (a-1) of statin inhibitors of HMG-CoA reductase in lactone form.
• Figure 7 illustrates examples of lipophilic moieties of six classes (a-f) of synthetic statin inhibitors of HMG-CoA reductase and their substituents.
• Figure 8 illustrates specific examples of lactone derivatives of each of four classes (a-d) of statin inhibitors of HMG-CoA reductase.
• Figure 9 illustrates two examples of modified closed ring structures of a ⁇ - lactone;
• Figure 9a represents a des-oxo-form (formula III);
• Figure 9b represents a ⁇ 5- lactam form (formula IV).
• Figure 10 illustrates a treatment approach in which compositions of the present invention produce a benefit in both MAP kinase-related and HMG-CoA reductase-related conditions.
• Figure 11 illustrates a design approach for developing compounds that inhibit MAP kinase and/or HMG-CoA reductase
• Figure 11a illustrates an approach in which known inhibitors of MAP kinases are systematically varied and tested for HMG-CoA reductase inhibitory activity
• Figure lib illustrates an approach in which known inhibitors of HMG-CoA reductase are systematically varied and tested for MAP kinase inhibitory activity
• Figure l ie illustrates an approach in which the lipophilic moiety of compounds of formula I or II is varied and tested for MAP kinase and/or HMG-CoA reductase inhibitory activity.
• One aspect of the present invention relates to compounds that inhibit protein kinases, e.g., protein kinases involved in inflammatory signaling cascades.
• these compounds can inhibit mitogen-activated protein kinases (MAP kinases).
• MAP kinases mitogen-activated protein kinases
• these compounds can inhibit p38 MAP kinases and/or stress-activated protein kinases/Jun N-terminal kinases (SAPKs/JNKs).
• SAPKs/JNKs stress-activated protein kinases/Jun N-terminal kinases
• these compounds can inhibit p38 ⁇ MAP kinase, hi preferred embodiments, such compounds exert anti-inflammatory effects in vitro and in vivo, e.g., as described in more detail below.
• Figure 1 illustrates some of the pathways involved in inflammatory signaling cascades and the interruption of certain of these pathways by a MAP kinase inhibitor. This figure provides an overview only, and is in no way intended to be limiting with respect to the present invention. For example, those skilled in the art will readily appreciate variations and modifications of the scheme illustrated. [0045] As Figure 1 illustrates, inflammatory signaling cascades transmit signals from outside a cell membrane 101 to the cytoplasm 102 and ultimately the nucleus 103.
• Pro ⁇ inflammatory cytokines 104 e.g., TNF- ⁇ and IL-I
• cellular stresses 105 and growth factors 106 initiate a signal transduction cascade leading to the activation of several serine/threonine kinases, including MKK3, MKK6 and p38 MAP kinase. Chakravarty et al, Annual Reports in Medicinal Chemistry, Chapter 18, Elsevier Science (2002).
• p38 MAP kinases exist in at least four isoforms, p38 ⁇ (expressed in all tissues), p38/3 (expressed in all tissues), p38 ⁇ (primarily expressed in skeletal tissue), and p38 ⁇ (primarily expressed in the lungs, kidneys, testes, pancreas and small intestine).
• a compound of the instant invention or a combination comprising one or more such compounds, e.g., by interaction with their shared Thr-Gly-Tyr dual phosphorylation activation motif and/or with their highly conserved amino acid sequences, e.g., the conserved binding pocket for ATP.
• p38 ⁇ MAP kinase is inhibited, p38cc MAP kinase serving as the primary MAP kinase associated with the pro-inflammatory cytokines.
• p38 ⁇ MAP kinase presents a target for small molecule therapeutics aimed at reducing cytokine production and treating associated inflammatory and/or autoimmune conditions.
• FIG. 1 illustrates, activation of p38 MAP kinase by upstream kinases leads to phosphorylation of downstream substrates, including MNK and MAPKAP-2, as well as transcription factors ATF-2, EUc-I, and MSK-I, which control transcription and production of pro-inflammatory cytokines.
• Figure 1 also illustrates points of action of an inhibitor that can reduce downstream effects of p38 MAP kinase, illustrated by double bars.
• a second aspect of the present invention relates to compounds that can inhibit the enzyme 3 -hydroxy-3 -methyl glutaryl-coenzyme A reductase (HMG-CoA reductase). These compounds can lower cholesterol levels in vitro and in vivo.
• HMG-CoA reductase 3 -hydroxy-3 -methyl glutaryl-coenzyme A reductase
• Figure 2a illustrates some of the pathways involved in cholesterol biosynthesis and some of the atherogenic mechanisms of hypercholesteremia, as well as the interruption of certain of these pathways by an HMG-CoA reductase inhibitor.
• This figure provides an overview only, and is in no way intended to be limiting. For example, those skilled in the art will readily appreciate variations and modifications of the scheme illustrated, and more detailed descriptions can be found in standard texts on biochemistry, metabolism, pathophysiology, and the like.
• HMG-CoA reductase catalyzes the committed, rate-limiting step of terpene and cholesterol synthesis in mammalian cells.
• HMG-CoA reductase acts on 3- hydroxy-3-methyl-glutaryl CoA (HMG-CoA) to produce mevalonate.
• Mevalonate is converted into cholesterol, which is carried in the blood mainly in two specialized particles known as low-density lipoprotein (LDL) and high-density lipoprotein (HDL).
• LDL low-density lipoprotein
• HDL high-density lipoprotein
• the pathway also produces other non-sterol isoprenoid products, such as farnesol, dolichol, and ubiquinone.
• LDL adheres to the arterial wall and is progressively oxidized.
• Extensively oxidized LDL is taken up by macrophages to form foam cells, a key feature of atherosclerosis. This leads to recruitment of monocytes and T-cells and secretion of cytokines in immune response cascades.
• HMG-CoA reductase inhibitors e.g., statins
• statins e.g., statins
• geranylgeranyl-PP decreases endothelial cell nitric oxide synthase (eNOS) expression, inhibiting nitric oxide-induced vasodilation.
• eNOS endothelial cell nitric oxide synthase
• Inhibition of HMG CoA reductase using a compound of the present invention, or a composition comprising one or more such compounds can also produce these effects, in certain embodiments, as discussed in detail below.
• a compound of the present invention can increase HDL levels ("good cholesterol") in some embodiments.
• HDL plays a role in carrying excess cellular cholesterol in what is known as the reverse cholesterol transport pathway.
• HDL is a complex of protein, lipids and cholesterol, which "scours" the walls of blood vessels to remove excess cholesterol.
• peripheral tissues e.g., vessel- wall macrophages
• Lecithin- cholesterol acyltransferase then esterifies free cholesterol to cholesteryl esters, converting pre- /3-HDL to mature spherical ce-HDL.
• a compound of the present invention can decrease serum LDL/HDL ratios, in some embodiments.
• Alzheimer's has been linked to several proteins of the cholesterol biosynthesis pathway.
• neuronal cells obtain cholesterol in two ways: through de novo synthesis or by internalization! through endosomal mechanisms. Cells which utilize the former synthesize cholesterol de novo in the endoplasmic reticulum and thereafter transport it to the cell membrane. Cells that utilize the latter internalize cholesterol synthesized by other neuronal cells such as astrocytes.
• cholesterol secreted via the ATP-binding cassette transporter 1 (ABCAl) transporter protein is taken up by brain HDL, containing apoliproteins E and J.
• ABCAl ATP-binding cassette transporter 1
• Cholesterol-containing brain HDL can be internalized by neuronal cells through an extracellular membrane receptor, called low-density lipoprotein-related receptor (LRP). Uptake is further assisted by LRP8 and very-low-density lipoprotein receptor (VLDLR). Polymorphisms in genes encoding cholesterol pathway proteins are putative risk factors for Alzheimer's. Such cholesterol pathway proteins include, e.g., the transport molecule apolipoprotein E, the uptake molecules LRP, LRP8, and VLDLR, as well as ABCAl (a catabolism-related molecule), and Cyp46 (an oxysterol producer). Wolozin, W., Cholesterol, statins and dementia (review), Curr. Op. Lipidol.
• AjS is produced when membrane bound amyloid precursor protein (APP) is cleaved by proteolytic enzymes, /5-secretase and ⁇ -secretase. Soluble A/3 fragments cluster with one another to form oligomers, then fibrillar A ⁇ aggregates, and eventually neuritic AjS plaques.
• Figure 2b illustrates some of the pathways involved in processing amyloid precursor protein, the role played by cholesterol in such pathways, as well as the interruption of certain of these pathways by an HMG-CoA reductase inhibitor. This figure provides an overview only, and is in no way intended to be limiting. For example, those skilled in the art will readily appreciate variations and modifications of the scheme illustrated, and more detailed descriptions can be found in standard texts on biochemistry, metabolism, pathophysiology, and the like.
• FIG. 2b a cholesterol-rich membrane is required for proteolysis of APP, which subsequently leads to the production of A ⁇ and eventual AjS plaque formation.
• Cell 1 of Figure 2b shows a neuronal cell in the process of synthesizing its own cholesterol de novo and then transporting it to the cell membrane to allow APP processing.
• Cell 2 shows a neuronal cell in the process of synthesizing and secreting it through the ABCAl transporter protein where brain HDL protein binds cholesterol.
• Cell 3 shows a neuronal cell in the process of internalizing the HDL- cholesterol complex by way of LRP. The subsequent transport of cholesterol to Cell 3's membrane allows APP processing to occur.
• Figure 2b also illustrates how inhibition of HMG CoA reductase in Cell 1 and Cell 2 using an HMG CoA reductase inhibitor can produce an inhibitory effect on cholesterol synthesis and thereby affect APP processing.
• the double bars indicate currently known effects of HMG-CoA reductase inhibitors (e.g., statins) on these processes.
• HMG-CoA reductase inhibitors have been found to reduce /3-secretase proteolysis of APP in cultured human cells overexpressing APP, while applying solubilized cholesterol to such cells resulted in a significant increase in AjS products, hi addition, reducing cellular cholesterol levels in hippocampal neurons has been shown to inhibit AjS formation.
• Reiss, A.B. et al. Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease (review), Neurobiology of Aging 25:977-89 (2004).
• Inhibition of HMG CoA reductase using a compound of the present invention, or a composition comprising one or more such compounds, can also produce these effects, in certain embodiments, as discussed in detail below.
• a third aspect of this invention relates to compounds that inhibit both MAP kinase and HMG-CoA reductase activities.
• Such compounds can inhibit both inflammatory responses and cholesterol biosynthetic pathways in vitro and in vivo, and can exert, for example, anti-inflammatory, lipid-modulating, and anti-atherogenic properties in vivo.
• such compounds can provide superior benefits in treating HMG-CoA reductase-related conditions, such as cardiovascular disease, compared with treatments that inhibit HMG-CoA reductase but not MAP kinase, due to the interplay between inflammatory and cardiovascular disorders, hi other embodiments, such compounds can provide superior benefits in treating MAP kinase-related conditions, such as inflammation, compared with treatments that inhibit MAP kinase but not HMG-CoA reductase, again due to the interplay between inflammatory and cardiovascular conditions.
• a fourth aspect of this invention relates to combinations of two or more compounds or forms of compounds that inhibit MAP kinase and/or HMG-CoA reductase activities, e.g., to produce one or more of the effects described above.
• Such combinations find particular use in treating inflammatory conditions.
• HMG-CoA reductase and MAP kinase may both play a role in certain inflammatory conditions, making the use of combination therapies particularly effective.
• HMG-CoA reductase and MAP kinase both have been implicated in inflammatory conditions of the skin.
• Acne is an example of a skin inflammatory conditon involving activities of both MAP kinase and HMG-CoA reductase.
• Acne results from the formation of a comedone followed by pericomedonian inflammation (or folliculitis).
• a comedone (or blackhead) forms when a pilo-sebaceous duct is obstructed and/or when there is increased production of sebum by a sebaceous gland. Formation of the comedone is followed by inflammation, e.g., resulting from bacterial proliferation due to seborrhoeic retention and/or overproduction of sebum.
• the bacteria are diphtheroid anaerobic bacteria such as Propionibacteria (acnes, granulosum, avidum).
• Propionibacteria acnes, granulosum, avidum
• pathways involving HMG-CoA reductase may also be involved.
• cholesterol and the metabolites thereof play a role in cohesion of epidermal cells, particularly corneocytes (cells constituting the stratum corneum).
• psoriasis is a chronic hyperproliferative skin condition wherein the subject exhibits inflammation, as well as excess proliferation of epidermal cells (scaling).
• the cause is thought to be an abnormal immune response to some element of the skin prompted by malfunctioning T cells. It is known in the art that multiple cellular events occur at the response site including increased cell adhesion molecule expression, upregulation of cytokines and growth factors, and penetration of the tissue by lymphocytes.
• HMG-CoA reductase inhibitors downregulate expression of cell adhesion molecules, inhibit the interaction between adhesion molecules required for leukocyte infiltration into inflammation sites, suppress the expression of T- helper- 1 chemokine receptors on T cells, and inhibit the expression of proinflammatory cytokines. Namazi, M.R., Experimental Dermatology, 13:337-39 (2004).
• HMG-CoA reductase and/or MAP kinase may also play a role in muscoskeletal inflammatory conditions, such as arthritis, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, and osteoporosis.
• osteoclasts large multinucleate cells formed from differentiated macrophages
• TNF- ⁇ , IFN- ⁇ and IL-I have been implicated in triggering excess osteoclast activity.
• Roux S. Bone loss. Factors that regulate osteoclast differentiation: an update (review), Arthritis Res., 2(6):451-456 (2000); Evans et al., Nitric oxide and bone (review), J Bone Miner Res. Mar; 11(3): 300-5 (1996).
• HMG-CoA reductase and/or MAP kinase may also play a role in respiratory inflammatory conditions.
• the inflammatory mediators IFN- ⁇ and/or TNF-ce are known in the art to mediate asthma and mucocutaneous inflammatory conditions such as allergic rhinitis.
• HMG-CoA reductase and/or MAP kinase may also play a role in gastrointestinal and urinogenital inflammatory conditions.
• gastrointestinal inflammatory conditons such as inflammatory bowel disease (including ulcerative colitis and Crohn's disease), celiac disease, intestinal infections, enterocolitis, and gastritis, exhibit chronic spontaneous relapsing enteropathies mediated by IFN- ⁇ and TNF- ⁇ .
• IFN- ⁇ and TNF- ⁇ urogenital inflammatory disorders are mediated by IFN- 7 and TNF-cc.
• HMG-CoA reductase and/or MAP kinase may also play a role in autoimmune diseases.
• HMG-CoA reductase inhibitors may have a beneficial effect on autoimmune disorders, such as multiple sclerosis (MS).
• MS multiple sclerosis
• Stuve, O., et al. The potential therapeutic role of statins in central nervous system autoimmune disorders (review), Cell MoI Life Sci. 2003 Nov;60(l 1):2483-91.
• MS is mediated by proinflammatory CD4 T (ThI) cells that recognize specific myelin proteins associated with MHC class II molecules on antigen presenting cells (APCs).
• ThI proinflammatory CD4 T
• HMG-CoA reductase inhibitors inhibit the production of iNOS, TNF-ct, IL-lbeta and IL-6 by microglia and astrocytes, both APCs.
• HMG-CoA reductase inhibitors also inhibit IFN- ⁇ -inducible class II expression on APCs, e.g., by inhibiting transcription of the IFN- ⁇ -inducible promoter, which may result in suppression of antigen presentation by APCs.
• HMG-CoA reductase inhibitors also bind lymphocyte function-associated antigen-1 (LFA-I), a beta2-integrin and prevent interaction with its ligand, ICAM-I, as well as T cell activation, suggesting a beneficial effect on MS independent of an inhibition of HMG-CoA reductase.
• LFA-I lymphocyte function-associated antigen-1
• ICAM-I a beta2-integrin
• T cell activation suggesting a beneficial effect on MS independent of an inhibition of HMG-CoA reductase.
• HMG-CoA reductase and/or MAP kinase may also play a role in graft rej ection after organ or tissue transplantation.
• HMG-CoA reductase inhibitors have been shown to significantly reduce the incidence of organ rejection, transplant vasculopathy, and natural killer (NK) cell cytotoxicity in recipients of heart transplants (Kobashigawa et al., Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression (review), Kidney hit. Suppl., Dec; 52:S112-5 (1995)) and kidney transplants (Katznelson, S. et al., The effect of pravastatin on acute rejection after kidney transplantation—a pilot study (review), Transplantation, May 27;61(10):1469-74 (1997)).
• inhibition of HMG CoA reductase and/or MAP kinase preferably inhibition of both, by a combination of compounds or forms of compounds of the present invention can also produce the aforementioned effects, in certain embodiments, as discussed in detail below.
• compositions of the present invention comprise compounds of formulas I and/or II, wherein I is a ⁇ -lactone (cyclic ester) and II is a 3,5-dihydroxy carboxylic acid in protonated form (formula Ha) or deprotonated form (formula lib).
• Figure 3 illustrates the inter-conversion between ⁇ -lactone and acid forms, where the ⁇ -lactone ring opens to the acid form with (reversible) addition of water, and further equilibriates to the deprotonated form with the loss of a proton to give the corresponding carboxylate ion. It will be recognized by those in the art that a rapid equilibrium exists between the protonated form of a carboxylic acid and its deprotonated carboxylate form, and that the deprotonated form predominates at neutral and basic pH. The deprotonated form is equivalent to a salt form of the acid.
• X preferably comprises a lipophilic moiety.
• a lipophilic moiety can refer to a molecular entity or a portion thereof having a tendency to dissolve in fat-like solvents, e.g., in a hydrocarbon solvent. Such moieties can also be referred to as hydrophobic moieties.
• X comprises a lipophilic moiety bearing at least one aromatic substituent.
• A represents a covalent bond or a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 carbons, optionally containing a heteroatom, such as O, N, or S.
• A is preferably a covalent bond, methylene, 1,2-oxamethylene, 1,2-ethylene, 1,2-ethynylene, 1,2-ethenylene, 1,3-propylene or 1,3-propenylene. More preferably, A is 1,2-ethylene or E- 1,2-ethenylene.
• Y is hydrogen or a lower alkyl, preferably hydrogen.
• Z is a hydroxy (-OH) group or hydrogen, preferably a hydroxy group .
• FIG. 3 a the configurations at each of two stereogenic centers of formulas I and II are not specified.
• the present invention includes each of the four possible stereoisomers arising from the two possible absolute configurations at each of the two stereogenic centers of formulas I and II.
• Compounds useful in this invention can include mixtures of the various stereoisomers or a pure stereoisomeric form.
• FIG. 3b illustrates an absolute configuration, designated (T, T), preferred in some embodiments of this invention.
• the designation (T, T) as used herein refers to the stereochemistry indicated, wherein wedge-shaped solid lines indicate bonds protruding above the plane of the illustration and dashed lines indicate bonds extending below the plane, so that the Y groups are above the plane, as are the ring oxygen of formula I and the corresponding hydroxy of formula II; while the Z groups are below the plane of the illustration.
• This (T, T) designation is used, rather than the conventional R or S designations, to reflect the fact that the actual absolute stereochemistry assignment will depend on the identity of A at one of the stereogenic centers, and the identity of Y and Z at the other stereogenic center.
• the 5-position of the 3,5-dihydroxy carboxylic acid becomes R if A is ethylene, whereas the stereochemistry becomes S if A is ethenylene.
• the stereochemistry becomes R or S at each of the sterogenic centers for each A, Y, and Z in the spatial arrangement depicted in Figure 3b.
• the (T, T) stereoisomer may comprise more than about 50%, more than about 70%, preferably more than about 90%, and more preferably more than about 98% of a mixture of more than one stereoisomer.
• optically active compounds of the present invention may be administered in enantiomerically pure (or substantially pure) form or as a mixture of detrorotatory and levorotatory enantiomers, such as in a racemic mixture.
• a subset of the compounds of formulas I and II are novel analogs of known inhibitors of MAP kinases, wherein X comprises a lipophilic MAP kinase inhibitor or a lipophilic moiety of a MAP kinase inhibitor.
• Figure 4 illustrates one or more non-limiting examples of each of twelve classes (a-1) of inhibitors of p38 ⁇ MAP kinase.
• preferred analogs include those derived from pyrazoles, such as compounds 1000-1004, illustrated in Figure 4a.
• preferred analogs include those derived form oxazoles, such as compound 1005, illustrated in Figure 4b.
• preferred analogs include derivatives of imidazoles, such as compounds 1006-1017, as illustrated in Figure 4c.
• preferred analogs include derivatives of pyrrolo[2,3- ⁇ ]pyrimidines, such as compounds 1018 and 1019, illustrated in Figure 4d.
• preferred analogs include those derived from diazaisoquinolinones, such as compound 1020, which is illustrated in Figure 4e.
• preferred analogs include those derived from 1,2-pyrazines, such as compound 1021, illustrated in Figure 4f.
• preferred analogs include derivatives of pyrroles, such as compound 1022, illustrated in Figure 4g.
• preferred analogs include derivatives of 4-aminobenzophenones, such as compound 1023, illustrated in Figure 4h. In some embodiments, preferred analogs include those derived from 3-amidobenzamides, such as compound 1024, illustrated in Figure 4i. In some embodiments, preferred analogs include those derived from pyridines, such as compound 1025, illustrated in Figure 4j. In some embodiments, preferred analogs include those derived from pyrirnidino[4,5-d]pyrirnidinones, such as compound 1026, illustrated in Figure 4k. In some embodiments, preferred analogs include those derived from indoles, such as compound 1027, illustrated in Figure 41.
• the present invention includes all stereoisomers arising from the possible absolute configurations at any stereo genie center of novel analogs of MAP kinase inhibitors of formula I and/or II, e.g., wherein X comprises a lipophilic MAP kinase inhibitor or a lipophilic moiety of a MAP kinase inhibitor. Mixtures of the various stereoisomers or pure or substantially pure stereoisomers forms may be used in various embodiments of the instant invention. [0075] In certain embodiments, lipophilic MAP kinase inhibitors are substituted or appended with A-lactone or A-acid moieties of formulas I and II, respectively, to form novel compounds of the present invention.
• Figure 5 illustrates lactone (formula T) derivatives of one example of each of the twelve classes of inhibitors of p38 ⁇ MAP kinase illustrated in Figure 4. It is to be understood that these represent examples of certain embodiments, and that other kinase inhibitors, attachment points, linking moieties (A), stereochemistries, etc., are expressly contemplated and included as other embodiments of the present invention. Further, the acid forms (formula II) of each and any of these examples are also a contemplated embodiment of the present invention.
• Figure 5a illustrates some preferred compounds of formula I wherein X comprises the pyrazole MAP kinase inhibitor compound 1000 or a lipophilic moiety thereof substituted or appended at three different positions with the A-lactone moiety, and wherein A is 1,2-ethenylene or 1,2-ethylene and Y is hydrogen.
• Figure 5b illustrates some preferred compounds of formula I wherein X comprises a lipophilic moiety of the oxazole MAP kinase inhibitor compound 1005, and wherein A is 1,2-ethenylene and Y is hydrogen.
• one of compound 1005 ' s appendages on the oxazole ring has been substituted by the A- lactone moiety of formula I.
• the two structures illustrated in Figure 5b are preferred compounds in some embodiments.
• Figure 5c illustrates some preferred compounds of formula I wherein X comprises the imidazole MAP kinase inhibitor compound 1006 or a lipophilic moiety thereof, A is 1,2-ethenylene and Y is hydrogen.
• the lipophilic moiety comprises all of compound 1006 except the 4-piperidyl moiety, which has been replaced with the A-lactone moiety of formula I.
• the lipophilic moiety comprises all of compound 1006 except the 2- methoxy-4-pyrimidinyl group, which has been replaced.
• the three structures illustrated in Figure 5c are preferred compounds in some embodiments of the present invention.
• Figure 5d illustrates some preferred compounds of formula I wherein X comprises a lipophilic moiety of pyrrolo[2,3- ⁇ ]pyrimidine MAP kinase inhibitor compound 1018, A is 1,2-ethenylene, and Y is hydrogen.
• the lipophilic moieties each comprise all but one of the aromatic substituents of compound 1018 in that the A-lactone moiety of formula I has been substituted for one of these substituents.
• the two structures illustrated in Figure 5d are preferred compounds in some embodiments.
• Figure 5e illustrates some preferred compounds of formula I wherein X comprises the diazaisoquinolinone MAP kinase inhibitor compound 1020 or a lipophilic moiety thereof, A is 1,2-ethenylene or 1,2-methenomethylene and Y is hydrogen, hi two of the illustrated examples, the lipophilic moiety comprises all but a thioaryl substituent, or all but one carbonyl oxygen substituents, of compound 1020 in that the A-lactone moiety of formula I has been substituted for one of each of these substituents.
• Figure 5f illustrates some preferred compounds of formula I wherein X comprises the 1,2-pyrazine MAP kinase inhibitor compound 1021 or a lipohilic moiety thereof, A is 1,2-ethenylene and Y is hydrogen.
• the lipophilic moiety comprises all but one aromatic substituent, or all but a benzene ring, or all but a piperazine ring of compound 1021 in that the A-lactone moiety of formula I has been substituted for one of each of these substituents.
• Figure 5g illustrates some preferred compounds of formula I wherein X comprises the pyrrole MAP kinase inhibitor compound 1022 or a lipophilic moiety thereof, A is 1,2-ethylene or 1,2-ethenylene, and Y is hydrogen, hi one of the illustrated examples, the lipophilic moiety comprises all but a carboxymethyl group of compound 1022 in that the A-lactone moiety of formula I has been substituted for this substituent.
• the three structures illustrated in Figure 5g represent preferred compounds in some embodiments.
• Figure 5h illustrates some preferred compounds of formula I wherein X comprises the 4-aminobenzophenone MAP kinase inhibitor compound 1023, A is 1,2-ethenylene, and Y is hydrogen.
• X comprises the 4-aminobenzophenone MAP kinase inhibitor compound 1023, A is 1,2-ethenylene, and Y is hydrogen.
• the compound 1023 structure is appended at three different positions with the A-lactone moiety of formula I.
• the three structures illustrated in Figure 5h represent preferred compounds in some embodiments.
• Figure 5i illustrates some preferred compounds of formula I wherein X comprises the 3-amidobenzamide MAP kinase inhibitor compound 1024, A is 1,2-ethenylene, and Y is hydrogen.
• the compound 1024 structure is appended at three different positions with the A-lactone moiety of formula I.
• Figure 5j illustrates some preferred compounds of formula I wherein X comprises the pyridine MAP kinase inhibitor compound 1025 or a lipophilic moiety thereof, A is 1,2- ethylene or 1,2-ethenylene, and Y is hydrogen.
• the lipophilic moiety comprises all but a hydroxymethyl group of compound 1025 in that the A-lactone moiety of formula I has been substituted for this substituent.
• the first and fourth structures illustrated in Figure 5j are preferred compounds in some embodiments.
• Figure 5k illustrates some preferred compounds of formula I wherein X comprises the pyrimidino[4,5-d]pyrimidinone MAP kinase inhibitor compound 1026 or a lipophilic moiety thereof, A is 1,2-methenomethylene, methylene, or 1,2-ethylene, and Y is hydrogen.
• the lipophilic moiety comprises all but the 4-hydroxycylohexyl moiety of compound 1026 in that the A-lactone moiety of formula I has been substituted for this substituent.
• Figure 51 illustrates some preferred compounds of formula I wherein X comprises the indole MAP kinase inhibitor compound 1027, A is methylene or 1,2-ethylene, and Y is hydrogen.
• X comprises the indole MAP kinase inhibitor compound 1027
• A is methylene or 1,2-ethylene
• Y is hydrogen.
• the compound 1027 structure is appended at three different positions with the A-lactone moiety.
• the second structure illustrated in Figure 51 is preferred in some embodiments.
• the compounds disclosed in this invention can be produced by methods known in the art as they are derivatives of classes of compounds known in the art. [0089]
• the present invention relates to these compounds, to pharmaceutical formulations comprising one of more of these compounds, e.g., in combination formulations, and to the use of such compounds and/or the corresponding acids of formula II in treating MAP kinase-related and/or HMG-CoA reductase-related conditions, as described in more detail below.
• a subset of the compounds of formulas I and II are novel analogs of known inhibitors of HMG-CoA reductase, wherein X comprises a lipophilic HMG-CoA reductase inhibitor, e.g., a statin, or a lipophilic moiety of an HMG-CoA reductase inhibitor.
• a statin can refer to any compound that can inhibit HMG-CoA reductase, generally comprising formula I or II.
• Known lipophilic inhibitors of HMG-CoA reductase include, for example, mevasatin, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, pitavastatin, glenvastatin, bervastatin, dalvastatin, eptastatin, dihydroeptastatin, itavastatin, L- 154819, advicor, L-654969, and other statin drugs used to treat disorders such as hypercholesterolemia.
• Statins are classified in the art as natural or synthetic statins depending on their origin. Natural stains include, for example, mevastatin, lovastatin, simvastatin, pravastatin, and the like. Synthetic statins include, for example, atorvastatin, fluvastatin, cerivastatin, rosuvastatin, pitavastatin, and glenvastatin.
• Figure 6 illustrates an example of each of twelve known classes (a-1) of statin inhibitors of HMG-CoA reductase in the lactone form of formula I. Figure 6a illustrates fluvastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 6b illustrates atorvastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 6c illustrates pitavastatin lactone, derivatives of which are preferred in certain preferred embodiments.
• Figure 6d illustrates cerivastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 6e illustrates rosuvastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 6f illustrates glenvastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 6g illustrates simvastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 6h illustrates lovastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 6i illustrates pravastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 6j illustrates mevastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 6k illustrates bervastatin lactone, derivatives of which are preferred in certain embodiments of the invention.
• Figure 61 illustrates dalvastatin lactone, derivatives of which are preferred in certain embodiments of the invention, hi particular, more preferred statin lactones are those derived from synthetic statins, and even more preferred stain lactones are those derived from atorvastatin, fluvastatin, rosuvastatin, cerivastatin, pravastatin and glenvastatin.
• FIG. 7 illustrates more specific examples of lipophilic moieties (X) derived from six classes (a-f) of synthetic statins and their substituents.
• Pi is tert-butyl, iso-propyl, cyclopropyl, 2-hydroxy-2-propyl, 1- hydroxycyclopropyl
• P 2 is hydrogen, fluorine, or -trifluoromethyl
• P 3 is hydrogen, cyano, methoxy, phenoxy, anilino, phenyhnethylamino, or amino
• P 4 is hydrogen, phenyl or phenylcarbamoyl
• P 5 is hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aniline, substituted aniline, phenyl ether, substituted phenyl ether, N-alkyl alkyl sulfonamido, N-alkyl aryl sulfonamide, N-alkyl alkanamid
• Figure 7a illustrates an example of an indole-based lipophilic moiety related to fluvastatin, preferred in some embodiments.
• Figure 7b illustrates two examples of imidazole-based lipophilic moieties related to atorvastatin, which are preferred in some embodiments.
• Figure 7c illustrates five examples of pyrrole-based lipophilic moieties related to atorvastatin, which are preferred in certain embodiments.
• Figure 7d illustrates three examples of quinoline-based lipophilic moieties related to pravastatin, preferred in some embodiments.
• Figure 7e illustrates four examples of pyridine-based lipophilic moieties related to cerivastatin, preferred in some embodiments.
• Figure 7f illustrates an example of a pyrimidine-based lipophilic moiety related to rosuvastatin, which is preferred in some embodiments.
• lipophilic derivatives of statins including, for example the lipophilic moieties of Figure 7, are substituted or appended with A— lactone or A-acid moieties of formulas I and II, respectively, to form novel compounds of the present invention.
• Figure 8 illustrates specific examples of lactone (formula I) derivatives of each of the four classes (a-d) of statins represented in Figure 7 and wherein each of Pi, P 2 , P 3 , P 4 , P 5 , and Q have been selected to give compounds preferred in some embodiments of the present invention.
• FIG. 8a illustrates selected indole-based lipophilic moieties related to fluvastatin, which are preferred in some embodiments (Family I).
• Figure 8b illustrates selected imidazole-based lipophilic moieties derived from atorvastatin, which are preferred in some embodiments (Family II).
• Figures 8c illustrates selected pyrrole-based lipophilic moieties derived from atorvastatin, which are preferred in some embodiments (Family III).
• Figure 8d illustrates selected quinoline-based lipophilic moieties related to pravastatin, which are preferred in some embodiments, divided amongst two families, Family IV and Family V.
• Figure 8e illustrates selected pyridine-based lipophilic moieties related to cerivastatin, which are preferred in some embodiments (Family VI).
• the present invention includes all stereoisomers arising from the possible absolute configurations at any stereo genie center of novel analogs of FJMG CoA reductase inhibitors of formula I and/or II, e.g., wherein X comprises a lipophilic HMG-CoA reductase inhibitor, e.g., a statin, or a lipophilic moiety of an HMG-CoA reductase inhibitor.
• X comprises a lipophilic HMG-CoA reductase inhibitor, e.g., a statin, or a lipophilic moiety of an HMG-CoA reductase inhibitor.
• Mixtures of the various stereoisomers or pure or substantially pure stereoisomeric forms maybe used in various embodiments of the instant invention.
• the compounds disclosed in this invention can be produced by methods known in the art as they are derivatives of classes of compounds known in the art.
• statins are described in Roth et al., J. Med. Chem., 34:357-366 (1991); Krause et al., J. DrugDev., 3(Suppl. l):255-257 (1990); and Karanewsky, et al., J. Med. Chem. 33:2952-2956 (1990). Examples are also provided in the Examples below. Further, specific examples of the present invention can be made by variations of methods known to those of skill in the art and provided herein, for example, where starting materials, solvents, and other reaction conditions are varied to optimize yields. [0099] In certain embodiments, the compounds of the present invention can be made using commercially available compounds as starting materials.
• lactones of formula I can be prepared from commercially available salts of HMG-CoA reductase inhibitors.
• commercially available calcium or sodium salts of atorvastatin, fluvastatin and rosuvastatin may be converted to their protonated free acid forms by extracting the salt forms from weakly acidic aqueous media into an aprotic organic solvent such as ethyl acetate.
• an aprotic organic solvent such as ethyl acetate
• lactone forms may be conveniently purified by any methods known in the art, including by column, preparative thin-layer, rotating, or high-pressure chromatography on silica gel columns using standard eluting solvent systems such as about 5:1 (v:v) acetone:ethyl acetate.
• compounds of the present invention can be made from modifying intermediates of synthesis pathways of known statins. For example, a group can be replaced by reactive groups such as an amino, halogen, or hydroxy group, or a metal derivative such as sodium, magnesium, or lithium, and these groups further reacted.
• Another aspect of the present invention relates to analogs of known lipophilic MAP kinase and/or HMG-CoA reductase inhibitors, e.g. statins, having structures modified to favor and/or enforce a closed ring structure, for example, a ring structure or cyclic form that is not hydrolyzed or not substantially hydrolyzed to its carboxylic acid or carboxylate forms.
• statins having structures modified to favor and/or enforce a closed ring structure, for example, a ring structure or cyclic form that is not hydrolyzed or not substantially hydrolyzed to its carboxylic acid or carboxylate forms.
• At least about 50%, at least about 75%, at least about 90%, and more preferably at least about 95% of the compound is in a ring structure of cyclic form at equilibrium, in situations where the compound is not substantially hydrolyzed.
• at least about 70%, at least about 80%, at least about 90%, and more preferably at least about 95%, and even more preferably at least about 98% of the compound is in a ring structure or cyclic form at equilibrium, in situations where the compound is not hydrolyzed.
• Figure 9 illustrates two examples of modified closed ring structures that are analogs of a ⁇ - lactone;
• Figure 9a represents a des-oxo-form (formula III), where the carbonyl oxygen is removed, thereby inhibiting hydrolytic ring opening.
• Figure 9b represents a ⁇ -lactam form (formula IV), where a nitrogen replaces an oxygen in the ring, which increases the hydrolytic stability of the cyclic form, hi these formulas, X comprises a lipophilic moiety, hi some preferred embodiments, X comprises a lipophilic MAP kinase inhibitor or a lipophilic moiety of a MAP kinase inhibitor, for example, the MAP kinase inhibitors of Figure 4, as well as lipophilic moieties of analogs of MAP kinase inhibitors, such as those of Figure 5.
• X comprises a lipophilic moiety of a statin, including, for example, the statins of Figure 6, as well as lipophilic moieties of statin analogs, such as those of Figures 7 and 8.
• X comprises a lipophilic moiety bearing at least one aromatic substituent, more preferably an aromatic moiety of a synthetic statin.
• A represents a covalent bond or a substituted or unsubstituted alkylene, alkenylene, or alkynylene linker of 2-6 carbons, optionally containing a heteroatom, such as O, N, or S.
• A is preferably a covalent bond, methylene, 1,2-oxamethylene, 1,2-ethylene, 1,2-ethynylene, 1,2-ethenylene, 1,3-propylene or 1,3-propenylene. More preferably, A is 1,2-ethylene or E- 1,2-ethenylene.
• Y is hydrogen or a lower alkyl, preferably hydrogen.
• Z is a hydroxy (-OH) group or hydrogen, preferably a hydroxy group.
• P 6 is hydrogen, aryl, substituted aryl, heteroaryl, substituted heteroaryl, alkaryl, substituted alkaryl, benzyl, substituted benzyl, napthylmethylene, or substituted napthlymethylene.
• P 6 is alkaryl or substituted alkaryl; more preferably P 6 is benzyl, substituted benzyl, napthylmethylene, or substituted napthlymethylene.
• each of the four possible stereoisomers arising from the two possible absolute configurations at each of the two stereo genie centers of formulas III and IV, are contemplated embodiments of the invention.
• an absolute configuration as illustrated in Figure 3b, depicted as (T, T) is preferred in some embodiments.
• des- oxo and ⁇ -lactam forms derived from synthetic statins including, for example, atorvastatin, fluvastatin, rosuvastatin, cerivastatin, pravastatin, and glenvastatin, are particularly preferred in some embodiments.
• Some embodiments are componds comprising novel series of substituted imidazoles, substituted pyrazoles, substituted pyrroles, substituted indoles, substituted pyridines, substituted pyrimidines, or substitued quinolines, some embodiments of which are discussed in more detail below.
• the present invention relates to these compounds, to pharmaceutical formulations comprising one of more of these compounds, e.g., in combination formulations, and to the use of such compounds and/or the corresponding acids of formula II in treating MAP kinase-related and/or HMG-CoA reductase-related conditions, as described in more detail below.
• methods described herein employ a subset of the compounds of formulas I and II that are substituted imidazoles of formula V Formula V where R 1 is
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl
• R 4 is optionally substituted
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• ethyl i.e., is -CH 2 -CH 2 -
• Preferred salts include those of calcium, sodium and potassium.
• the N at the 3-position of the imidazole ring is protonated (e.g., reversibly protonated) or optionally substituted.
• the R 4 pyrimidinyl, pyridinyl or imidazolyl ring is attached via any available carbon or nitrogen atom of the ring.
• substituted can include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted with one or more of the disclosed or claimed substituent moieties, singly or pluraly.
• Alkyl as well as other groups having the prefix “alk”, such as alkoxy, alkanoyl, can refer to optionally substituted carbon chains which may be linear or branched or combinations thereof.
• alkyl groups include, e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, iso- sec- and tert-butyl, pentyl, hexyl, heptyl, octyl, nonyl, and the like.
• Aryl can refer to optionally substituted mono- or bicyclic aromatic rings containing only carbon atoms.
• the term can also include aryl group fused to a monocyclic cycloalkyl or monocyclic cycloheteroalkyl group in which the point of attachment is on an aromatic portion.
• aryl groups include, e.g., phenyl, naphthyl, indanyl, indenyl, tetrahydronaphthyl, 2,3-dihydrobenzofuranyl, dihydrobenzopyranyl, 1,4- benzodioxanyl, and the like.
• Heteroaryl can refer to an optionally substituted mono- or bicyclic aromatic ring containing at least one heteroatom (an atom other than carbon), such as N, O and S, with each ring containing about 5 to about 6 atoms.
• heteroaryl groups include, e.g., pyrrolyl, isoxazolyl, isothiazolyl, pyrazolyl, pyridyl, oxazolyl, oxadiazolyl, thiadiazolyl, thiazolyl, imidazolyl, triazolyl, tetrazolyl, furanyl, triazinyl, thienyl, pyrimidyl, pyridazinyl, pyrazinyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, benzothiophenyl, furo(2,3-b)pyridyl, quinolyl, indolyl, isoquinolyl, and the like.
• Halogen can include fluorine, chlorine, bromine and iodine.
• R, R', etc. generally refer to any non-aromatic group, including, e.g., substituted or unsubstituted alkyl groups, unless specifically defined otherwise.
• Ar, Ar', etc. generally refer to substituted or unsubstituted aromatic groups, including, e.g., aryls and heteroaryls.
• n is 0 1, 2 or 3.
• Ri has the following stereochemistry:
• Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and/or Z geometric isomers. In some embodiments, the E geometric isomer is preferred.
• tautomers Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixtures thereof are encompassed within compounds of formula V.
• the compounds of formula V are MAP kinase inhibitors and/or are used in the methods wherein an inhibition of MAP kinase is desired, e.g., in the treatment of MAP kinase-related conditions.
• n is 0 or any integer, preferably 0, 1 or 2; and R 4 is optionally substituted
• R 4 when R 4 is the pyridinyl ring optionally substituted with one or more substituents selected from halogen atoms and hydroxyl, C 1-3 alkyl, C 1-3 alkoxy and trifluoromethyl groups, then the bridging group OfR 1 is -CH 2 -CH 2 -.
• R 4 substituents may be present on one or more vacant positions of a carbon and/or heteroatom of the pyrimidinyl, pyridinyl or imidazolyl rings.
• Particularly preferred R 4 substitutents include -NH-phenyl, -NH-CH 3 , and NH 2 groups, hi still some embodiments, R 4 substitutents include N-oxides, for example:
• R 4 can be any organic radical
• a particularly preferred group of compounds of formula V are those wherein R 2 is a C 1-6 alkyl group optionally substituted with one to three halogen atoms for example a trifluoromethyl or a C 1-4 alkyl group, more particularly a C 3 - 4 branched alkyl group, e 1-methylpropyl.
• R 2 is isopropyl, t-butyl, -CF 3 , phenyl,
• R 5 is an optionally substituted phenyl group
• R 5 is a substituted phenyl group
• R 5 substituents include halogen atoms e.g. fluorine, bromine, chlorine, methoxy, methyl, ethyl, hydroxy or trifluoromethyl groups.
• Preferred substituted R 5 substituents include halophenyl such as 4-fluorophenyl, 4-chlorophenyl, 3- chlorophenyl, 3-bromophenyl, 3,5-dibromophenyl, 3,5-dichlorophenyl, alkyl-halophenyl such as 5-chloro-2-methylphenyl, 4-fluoro-2-methylphenyl, 3 5 5-dimethyl-4-fluorophenyl, 4-chloro-3,5-dimethylphenyl and 3,5-diethyl-4-fluorophenyl, alkylphenyl such as 4- methylphenyl, 3,5-dimethylphenyl, hydroxyphenyl, methoxyphenyl or 3- trifluoromethylphenyl. Particularly preferred is 4-fluorophenyl or 3- trifluoromethylphenyl.
• a particularly preferred group of compounds are those wherein R 2 is a phenyl, trifluoromethyl, t-butyl or more especially an isopropyl group; R 5 is a phenyl, 3- chlorophenyl, 3 -trifluoromethylphenyl, 4-chlorophenyl, 4-fluorophenyl, 4-fluoro-2- methylphenyl, 3,5-diethyl-4-fluorophenyl or 3,5-dimethyl-4-fluorophenyl group; and R 4 comprises a 4-pyridinyl group, a 4-pyrimidinyl group, or a 4-imidazolyl group, a 2- aminophenyl-4-pyridinyl group, a 2-aminophenyl-4-pyrimidinyl group, a 2-aminomethyl- 4-pyridinyl group, or a 2-aminomethyl-4-pyrimidinyl group, especially 4-pyrimidinyl, 4- pyridinyl, 2-amin
• n is 0 or any integer, preferably 0, 1 or 2;
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyrimidinyl ring is optionally substituted; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• the pyrimidinyl ring is unsubstituted.
• the pyrimidinyl ring is substituted, e.g., with optionally substituted amino groups, especially -NH-CH 3 or -NH-phenyl; or with -0-CH 3 .
• Another preferred group of compounds of formula V are compounds of formula Vb wherein R 1 is
• n is O or any integer, preferably O, 1 or 2;
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyridinyl ring is optionally substituted, with the proviso that when the pyridinyl ring is unsubstituted or substituted with one or more substituents selected from halogen atoms and hydroxyl, C 1-3 alkyl, C 1-3 alkoxy and trifluoromethyl groups, then the bridging group OfR 1 is -CH 2 -CH 2 -; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• the pyridinyl ring is unsubstituted.
• the pyridinyl ring is substituted, e.g., with optionally substituted amino groups, especially, -NH 2 Or-NH-CH 3 .
• Compounds of the formula V may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example MeOH or ethyl acetate or a mixture thereof.
• the pair of enantiomers may be separated into individual stereoisomers by, for example the use of an optically active amine as a resolving agent or on a chiral EDPLC column. Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These include chiral chromatography, derivatization with a chiral auxiliary followed by separation by chromatography or crystallization, and fractional crystallization of diastereomeric salts.
• any enantiomer of a compound of the general formula V may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
• compounds of formula V are administered as enantiomerically pure (or substantially enantiomerically pure) formulations.
• Example 13 provides examples of synthesizing (3i?,5i?)-7-(2,5-diphenyl-4-(pyridin-4-yl)-lH-imidazol-l-yl)-3,5- dihydroxyheptanoic acid, calcium salt and (3i?,5i?)-7-(5-(4-fluorophenyl)-2-phenyl-4- (pyridin-4-yl)-lH-imidazol-l-yl)-3,5-dihydroxyheptanoic acid, calcium salt, via sidechain condensation.
• Example 14 provides examples of synthesizing (3 S, 5 S), (3R,5R)-6-(5-(4- fluorophenyl)-2-phenyl-4-(pyrimidin-4-yl)-lH-imidazol-l-yl)-3,5-dihydroxyhexanoic acid, calcium salt via an N-alkylation.
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl, or heteroaryl
• R 4 is optionally substituted and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• ethyl i.e., is -CH 2 -CH 2 -
• Preferred salts include those of calcium, sodium and potassium.
• the N at the 2-position of the pyrazole ring is protonated (e.g., reversibly protonated) or optionally substituted.
• Also contemplated within the scope of Formula VI are compounds where the R 4 pyrimidinyl, pyridinyl or imidazolyl ring is attached via any available carbon or nitrogen atom of the ring.
• substituted can include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted with one or more of the disclosed or claimed substituent moieties, singly or pluraly.
• Compounds of formula VI contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, pure or substantially pure isomeric forms, single enantiomers, diastereomeric mixtures and individual diastereomers. The present invention is meant to comprehend all such isomeric forms of the compounds of formula VI.
• n is 0, 1, 2 or 3.
• Ri has the following stereochemistry:
• Some of the compounds described herein contain olefmic double bonds, and unless specified otherwise, are meant to include both E and/or Z geometric isomers. In some embodiments, the E geometric isomer is preferred.
• tautomers Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixtures thereof are encompassed within compounds of formula VI.
• the compounds of formula VI are MAP kinase inhibitors and/or are used in the methods wherein an inhibition of MAP kinase is desired, e.g., in the treatment of MAP kinase-related conditions.
• n is 0 or any integer, preferably 0, 1 or 2; and R 4 is optionally substituted
• R 2 is an alkyl from 1-3 carbon atoms, trifiuoromethyl, diakylamino in which alkyl is 1-4 carbon atoms, pyrrolidino, piperidino, morpholino or piperazino, then R 4 is substituted.
• R 4 substituents may be present on one or more vacant positions of a carbon and/or heteroatom of the pyrimidinyl, pyridinyl or imidazolyl rings.
• suitable substituents include, but are not limited to, oxygen, fluorine, chlorine, bromine or iodine atoms or methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, hydroxy, or optionally substituted amino groups.
• Particularly preferred R 4 substitutents include -OCH 3 and — NH-phenyl groups.
• R 4 substitutents include N-oxides, for example:
• R 4 can be any organic radical
• R 2 groups include lower alkyl, e.g., an alkyl from one to four carbon atoms, dimethylamino, or 1-methylpropyl, and especially isopropyl, phenyl, or hydrogen.
• R 5 is phenyl which is monosubstituted with alkyl of from one to three carbon atoms, fluorine, chlorine, or trifluoromethyl; or phenyl which is disubstituted with two groups independently selected from alkyl of from one to three carbon atoms, fluorine, chlorine, or trifluoromethyl. Particularly preferred is 4-fluorophenyl or 3-trifluoromethylphenyl.
• a particularly preferred group of compounds are those wherein R 2 is a hydrogen, phenyl, or isopropyl group; R 5 is a 3-trifluoromethylphenyl or 4-fluorophenyl group; and R 4 comprises a 4-pyridinyl group, a 4-pyrimidinyl group, or a 4-imidazolyl group, especially 2-methoxy-4-pyrimidinyl, 2-aminophenyl-4-pyrimidinyl, or 2- aminophenyl-4- ⁇ yridinyl.
• R 5 is a 3-trifluoromethylphenyl group are especially preferred
• a preferred group of compounds of formula VI are compounds of Formula Via
• n is 0 or any integer, preferably 0, 1 or 2;
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyrimidinyl ring is optionally substituted; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof, with the proviso that when R 2 is an alkyl from 1-3 carbon atoms, trifluoromethyl, diakylamino in which alkyl is 1-4 carbon atoms, pyrrolidino, piperidino, morpholino or piperazino, then R 4 is substituted.
• the pyrimidinyl ring is unsubstituted.
• the pyrimidinyl ring is substituted, e.g., with optionally substituted amino groups, especially — NH-phenyl, or with optionally substituted alkoxy groups, especially — 0-CH 3 .
• n is O or any integer, preferably O, 1 or 2;
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyridinyl ring is optionally substituted; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof, with the proviso that when R 2 is an alkyl from 1 -3 carbon atoms, trifluoromethyl, diakylamino in which alkyl is 1-4 carbon atoms, pyrrolidino, piperidino, morpholino or piperazino, then R 4 is substituted.
• the pyridinyl ring is unsubstituted.
• the pyridinyl ring is substituted, e.g., with optionally substituted amino groups, especially, -NH-phenyl.
• compositions of the present invention include, but are not limited to, the following:
• Compounds of the formula VI may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example MeOH or ethyl acetate or a mixture thereof.
• the pair of enantiomers may be separated into individual stereoisomers by, for example the use of an optically active amine as a resolving agent or on a chiral HPLC column.
• Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These include chiral chromatography, derivatization with a chiral auxiliary followed by separation by chromatography or crystallization, and fractional crystallization of diastereomeric salts.
• any enantiomer of a compound of the general formula VI may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration, hi preferred embodiments, compounds of formula VI are administered as enantiomerically pure (or substantially enantiomerically pure) formulations.
• Example 10 provides examples of synthesizing four N-pyridyl pyrazoles and Example 11 provides examples of synthesizing eight N-pyrimidinyl pyrazoles.
• Example 11 provides examples of synthesizing eight N-pyrimidinyl pyrazoles.
• n 0 or any integer
• R 2 is optionally substituted alkyl, aryl or heteroaryl
• R 3 is any substituent
• R 4 is optionally substituted
• R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• ethyl i.e., is -CH 2 -CH 2 -
• Preferred salts include those of calcium, sodium and potassium.
• R 4 pyrimidinyl, pyridinyl or imidazolyl ring is attached via any available carbon or nitrogen atom of the ring.
• R 1 , R 2 , etc. are to be chosen in conformity with well-known principles of chemical structure connectivity.
• substituted can include multiple degrees of substitution by a named substitutent. Where multiple substituent moieties are disclosed or claimed, the substituted compound can be independently substituted with one or more of the disclosed or claimed substituent moieties, singly or pluraly.
• Compounds of formula VII contain one or more asymmetric centers and can thus occur as racemates and racemic mixtures, pure or substantially pure isomeric forms, single enantiomers, diastereomeric mixtures and individual diastereomers.
• the present invention is meant to comprehend all such isomeric forms of the compounds of formula
• n 0, 1, 2 or 3.
• R 1 has the following stereochemistry:
• tautomers Some of the compounds described herein may exist with different points of attachment of hydrogen, referred to as tautomers. Such an example may be a ketone and its enol form known as keto-enol tautomers. The individual tautomers as well as mixtures thereof are encompassed within compounds of formula VII.
• the compounds of the formula VII are MAP kinase inhibitors and/or are used in the methods wherein an inhibition of MAP kinase is desired, e.g., in the treatment of MAP kinase-related conditions.
• n is 0 or any integer, preferably 0, 1 or 2; and R 4 is optionally substituted
• R 4 substituents may be present on one or more vacant positions of a carbon and/or heteroatom of the pyrimidinyl, pyridinyl or imidazolyl rings.
• suitable substituents include, but are not limited to, oxygen, methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, hydroxy, or optionally substituted amino groups.
• R 4 is the pyridinyl ring substituted with one or more optionally substituted amino groups.
• R 4 substirutents include -OCH 3 , -NH 2 , -NH-CH 3 , and -NH-Phenyl.
• R 4 substirutents include N-oxides, for example:
• R 4 can be any organic radical
• a particularly preferred group of compounds of formula VII are those wherein R 2 is a branched alkyl group such as isopropyl or isobutyl. Particularly preferred is isopropyl.
• Another preferred class of compounds of formula VII are those compounds wherein R 5 is a substituted phenyl group and preferably contains from 1 to 3 substituents.
• R 5 substituents include halogen atoms e.g. fluorine, bromine, chlorine, methoxy, methyl, ethyl, hydroxy, fluorophenyl or trifluoromethyl groups.
• Particularly preferred is 4-fluorophenyl or 3-trifluoromethylphenyl.
• Another preferred class of compounds of formula VII are those compounds wherein R 3 is -CONH-W, where W is optionally substituted phenyl.
• suitable substituents include, but are not limited to, fluorine, chlorine, bromine or iodine atoms or methyl, ethyl, n-propyl, isopropyl, methoxy, ethoxy, n-propoxy, isopropoxy, trifluoromethyl, hydroxy, or optionally substituted amino groups.
• Particularly preferred are compounds in which W is unsubstituted phenyl.
• a particularly preferred group of compounds are those wherein R 2 is isopropyl
• R 5 is 4-fluorophenyl;
• R 3 is -CONH-phenyl; and
• R 4 comprises a 4-pyrimidinyl group, 2- methyl-4-pyridinyl group, a 2-amino-4-pyridinyl group, a 2-aminophenyl-4-pyridmyl group, a 2-aminomethyl-4-pyrimidinyl group, a 2-aminomethyl-4-pyridinyl group, or a 4- imidazolyl group, especially 4-primidinyl, 2-methoxy-4-pyrimidinyl, 2-amino-4- pyrimidinyl, or 2-aminophenyl-4-pyrimidinyl.
• a preferred group of compounds of formula VII are compounds of formula Vila wherein R 1 is
• n is 0 or any integer, preferably 0, 1 or 2;
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyrimidinyl ring is optionally substituted; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• the pyrimidinyl ring is unsubstituted.
• the pyrimidinyl ring is substituted, e.g., with optionally substituted amino groups, especially -NH 2 or -NH-phenyl, or with optionally substituted alkoxy groups, especially -0-CH 3 .
• n is 0 or any integer, preferably 0, 1 or 2;
• R 2 is optionally substituted alkyl, aryl, or heteroaryl; the pyridine ring is substituted; and R 5 is optionally substituted aryl or heteroaryl, or a salt thereof.
• Particularly preferred examples of compounds of the present invention include, but are not limited to, the following:
• Compounds of the formula VII may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example MeOH or ethyl acetate or a mixture thereof.
• the pair of enantiomers may be separated into individual stereoisomers by, for example the use of an optically active amine as a resolving agent or on a chiral HPLC column.
• Racemic mixtures can be separated into their individual enantiomers by any of a number of conventional methods. These include chiral chromatography, derivatization with a chiral auxiliary followed by separation by chromatography or crystallization, and fractional crystallization of diastereomeric salts.
• any enantiomer of a compound of the general formula VII may be obtained by stereospecific synthesis using optically pure starting materials or reagents of known configuration.
• compounds of formula VII are administered as enantiomerically pure (or substantially enantiomerically pure) formulations.
• compositions comprising combinations of a statin lactone with one or more additional active agents, preferably a pharmacologically active agent.
• Some embodiments include combinations comprising two or more statin lactones; two or more hydroxy acid forms of a statin; two or more non- statin anti-inflammatory agents; a statin lactone and a hydroxy acid form of a statin; a non- statin anti-inflammatory agent and a statin lactone; and a non-statin anti-inflammatory agent and a hydroxy acid form of a statin, hi some embodiments, such combinations have molar ratios of about 99: 1 to about 1 :99.
• the range of molar ratios is selected from about 80:20 to about 20:80; about 75:25 to about 25:75, about 70:30 to about 30:70, about 66:33 to about 33:66; about 60:40 to about 40:60; about 50:50; and about 90:10 to about 10:90. More preferably the molar ratio is about 1 :9, and most preferably about 1:1.
• a statin lactone is combined with the hydroxy acid form of the same or a different statin, or a pharmaceutically acceptable salt thereof.
• the statin lactone and hydroxy acid (or salt) forms may be combined in molar ratios of about 99:1 to about 1:99.
• the range of molar ratios of statin lactone: hydroxy acid (or salt) is selected from about 80:20 to about 20:80; about 75:25 to about 25:75, about 70:30 to about 30:70, about 66:33 to about 33:66, about 60:40 to about 40:60; about 50:50; and about 90:10 to about 10:90. More preferably the molar ratio of statin lactone: hydroxy acid (or salt) is about 1 :9, and most preferably about 1:1.
• the statin lactone is preferably at least one lactone selected from fluvastatin lactone, simvastatin lactone, lovastatin lactone, rosuvastatin lactone, pitavastatin lactone, glenvastatin lactone, cerivastatin lactone, pravastatin lactone, mevastatin lactone, bervastatin lactone and dalvastatin lactone, and most preferably is atorvastatin lactone.
• the statin hydroxy acid (or salt) is preferably at least one acid (or salt) selected from fluvastatin, simvastatin, lovastatin, rosuvastatin, pitavastatin, glenvastatin, cerivastatin, pravastatin, mevastatin, bervastatin and dalvastatin, and most preferably is atorvastatin and/or pitavastatin.
• the calcium salt of atorvastatin and/or the sodium salt of pitavastatin may be used.
• Example 4 describes a gel formulation comprising atorvastatin lactone and atorvastatin calcium, at a ratio of 1 : 1.
• Example 4b describes a tablet formulation comprising atorvastatin lactone and atorvastatin calcium, at a ratio of 1 : 1.
• Example 4c describes a tablet formulation comprising atorvastatin lactone and pitavastatin calcium, at a ratio of 1 : 1.
• a statin lactone is combined with a non-statin anti-inflammatory agent.
• the statin lactone and non-statin anti-inflammatory agent may be combined in molar ratios of about 99: 1 to about 1 :99.
• the range of molar ratios of statin lactone: non-statin anti-inflammatory agent is selected from about 80:20 to about 20:80; about 75:25 to about 25:75, about 70:30 to about 30:70, about 66:33 to about 33:66; about 60:40 to about 40:60; about 50:50; and about 90:10 to about 10:90.
• statin lactone is preferably at least one lactone selected from fluvastatin lactone, simvastatin lactone, lovastatin lactone, rosuvastatin lactone, pitavastatin lactone, glenvastatin lactone, cerivastatin lactone, pravastatin lactone, mevastatin lactone, bervastatin lactone and dalvastatin lactone, and most preferably is atorvastatin lactone.
• a non-statin anti-inflammatory agent can be any agent that is not a statin lactone or a hydroxy acid form of a statin or salt thereof.
• the non-statin anti ⁇ inflammatory agent can be selected from among immunosuppressive agents, steroidal anti ⁇ inflammatory agents, anti-histamines, mast cell stabilizers and anti-autocoids, protein kinase inhibitors, MAP kinase inhibitors, p38 MAP kinase inhibitors, disease-modifying anti-rheumatic drugs (DMARDs) and, more preferably, non-steroidal anti-inflammatory agents (NSAIDs).
• Preferred immunosuppressive agents include, e.g., mycophenolate mofetil, cyclosporine, azathioprine, tacrolimus, pimecrolimus, sirolimus, and the like.
• Preferred steroidal anti-inflammatory agents include, e.g., prescription and nonprescription topical and aerosol corticosteroids, cortisone, cortisone acetate, hydrocortisone, dexamethasone, dexamethasone phosphate salts, prednisone, prednisolone phosphate salts, prednisolone, methyprednisolone, methylprednisolone acetate, beclomethasone, beclomethasone dipropionate, budesonide, ciclesonide, flunisolide, triamcinolone acetonide, and the like.
• NSAIDs non-steroidal anti-inflammatory agents
• Preferred non-steroidal anti-inflammatory agents include, e.g., salicylates, acetyl salicylic acid, sodium salicylate, colchicine, choline magnesium trisalicylate, salsalate, diflunisal, salicylsalicylic acid, sulfasalazine, olsalazine, indomethacin, sulindac, etodolac, macrolide immunosuppressives, tolmetin, clobetasol, dapsone, diflorasone, halobetasol, diclofenac, ketorolac, ibuprofen, naproxen, flurbiprofen, ketoprofen, fenoprofen, oxaprozin, mefanamic acid, meclofenamic acid, para- aminophenols, propionic acids, piroxicam, tenoxicam, meloxicam
• Example 4 Additional details of compositions comprising a statin lactone combined with a non-statin anti-inflammatory agent are provided in Example 4. Specifically, Example 4d describes an ointment comprising atorvastatin lactone and the non-statin anti ⁇ inflammatory agent naproxen sodium, at a ratio of 1 : 1. Example 4e describes an ointment comprising atorvastatin lactone and the non-statin anti-inflammatory agent diclofenac, at a ratio of 1:1.
• Example 4f describes a rectal suppository comprising atorvastatin lactone and the non-statin anti-inflammatory agent aminosalicylic acid, at a ratio of 1 :9.
• Examples 4g, 4h, and 4i describe an ointment, a gel and a cream, respectively, each comprising atorvastatin lactone and the non-statin anti-inflammatory indomethacin, each at a ratio of
• a composition comprising two or more of the aforementioned compounds, forms, and/or agents provides a synergistic effect.
• a synergistic effect can refer to one in which two or more compounds, forms and/or agents work together to produce a total effect superior to and/or greater than that of any one compound, form and/or agent alone.
• the total effect may be a greater percentage increase in inhibition of a MAP kinase and/or a greater percentage increase in the inhibition of a MAP kinase-related in vitro and/or in vivo effect and/or a greater percentage increase in effectiveness in treating a MAP kinase-related condition.
• a synergistic effect may be at least about a 5%, at least about a 10%, at least about a 15%, at least about a 20%, at least about a 30%, at least about a 40%, at least about a 50%, at least about a 60%, at least about a 70%, or at least about an 80% greater increase.
• combinations of a statin lactone and one or more other active agents show a synergistic effect on reducing or inhibiting inflammation.
• use of a combination of the present invention may provide a greater percentage decrease in swelling due to inflammation compared to the effect using one or other of components of the combination alone.
• a combination of atorvastatin lactone with atorvastatin hydroxy acid (or salt); atorvastatin lactone with pitavastatin hydroxy acid (or salt); or atorvastatin lactone with indomethacin produce synergistic effects on reducing or inhibiting inflammation, compared to the effect using atorvastatin lactone alone, atorvastatin hydroxy acid (or salt) alone, pitavastatin hydroxy acid (or salt) alone, and/or indomethacin alone.
• the atorvastatin lactone may act by inhibiting p38 ⁇ MAP kinase, centrally involved in inflammatory signaling cascades as discussed above.
• Example 8 Additional details or such combinations providing synergistic effects on inflammation reduction or inhibition are provided in Example 8 below, e.g., where treatment with formulations comprising a combination of atorvastatin lactone and the non- statin anti-inflammatory agent indomethacin provides synergistic inhibitory effects on inflamamtion.
• Another aspect of the present invention relates to methods of using pharmaceutical compositions and kits comprising compounds described herein to treat kinase-related and/or reductase-related compounds, preferably MAP kinase-related and/or HMG-CoA reductase-related conditions, as well as novel uses of known compounds for the treatment of MAP kinase-related conditions, and novel combinations for the treatment of MAP kinase- and/or HMG CoA reductase-related conditions, especially inflammatory conditions.
• the present invention provides methods, pharmaceutical compositions, and kits for the treatment of animal subjects.
• animal subject as used herein includes humans as well as other mammals.
• treating as used herein includes achieving a therapeutic benefit and/or a prophylactic benefit.
• therapeutic benefit is meant eradication or amelioration of the underlying disorder being treated.
• therapeutic benefit includes eradication or amelioration of the underlying arthritis.
• a therapeutic benefit is achieved with the eradication or amelioration of one or more of the physiological symptoms associated with the underlying disorder such that an improvement is observed in the patient, notwithstanding the fact that the patient may still be afflicted with the underlying disorder.
• a MAP kinase inhibitor of the present invention provides therapeutic benefit not only when rheumatoid arthritis is eradicated, but also when an improvement is observed in the patient with respect to other disorders or discomforts that accompany rheumatoid arthritis, like stiffness or swelling in the joints.
• compositions of the present invention can provide therapeutic benefit in ameliorating other symptoms associated with MAP kinase-related conditions, e.g., inflammatory and/or autoimmune conditions, including redness, rashes, swelling, itching, irritation, dryness, scaling, flaking, pain, temperature increase, loss of normal function, and the like.
• a pharmaceutical composition of the invention may be administered to a patient at risk of developing a MAP kinase-related condition and/or a HMG-CoA reductase-related condition, or to a patient reporting one or more of the physiological symptoms of such conditions, even though a diagnosis of the condition may not have been made. Administration may prevent the condition from developing, or it may reduce, lessen, shorten and/or otherwise ameliorate the condition that develops.
• Administration may prevent the condition from developing, or it may reduce, lessen, shorten and/or otherwise ameliorate the condition that develops.
• MAP kinase-related condition refers to a condition in which directly or indirectly reducing the activity of a protein kinase involved in signaling cascades of an allergic, inflammatory and/or an autoimmune response is desirable, and/or directly or indirectly reducing the production and/or effects of one or more products of the protein kinase is desirable.
• a MAP kinase-related condition may involve over-production or unwanted production of one or more pro- inflammatory cytokines, such as tumor necrosis factor- ⁇ (TNF- ⁇ ), interleukin-lj ⁇ (IL- 1/3), or other chemical messengers of signal transduction pathways associated with inflammation (including responses to and expression of TNF-ce and IL- 1/3), apoptosis, growth and differentiation.
• pro-inflammatory cytokines such as tumor necrosis factor- ⁇ (TNF- ⁇ ), interleukin-lj ⁇ (IL- 1/3), or other chemical messengers of signal transduction pathways associated with inflammation (including responses to and expression of TNF-ce and IL- 1/3), apoptosis, growth and differentiation.
• Examples of MAP kinase-related conditions include but are not limited to allergic, inflammatory and autoimmune conditions, such as, for example, ocular allergic, ocular inflammatory and/or ocular autoimmune conditions; allergic, inflammatory and/or autoimmune conditions of the ear; allergic, inflammatory and/or autoimmune conditions of the skin and skin structures; gastrointestinal allergic, gastrointestinal inflammatory and/or gastrointestinal autoimmune conditions; respiratory allergic, respiratory inflammatory and/or respiratory autoimmune conditions; as well as arthritis, rheumatoid arthritis, and/or other inflammatory/autoimmune diseases of the musculoskeletal system; osteoarthritis; vascular inflammatory conditions, vasculitis, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), Celiac sprue, acne, psoriasis (as well as other papulosquamous disorders such as lichen planus), topical dermatitis; atopic dermatitis (including eczema), irritant contact dermatitis;
• MAP kinase-related conditions include ageing, photo-ageing, cachexia, leprosy, Leishmaniasis, asthma, chronic pelvic pain, inflammatory muscle disease, allergic rhinitis (hay fever), gastritis, vaginitis, conjunctivitis, interstitial cystitis, chronic fatigue syndrome, osteoporosis, scleroderma, and the like.
• MAP -kinase related conditions can also include diabetes, Ii chronic obstructive pulmonary disease, as well as cardiovascular-related conditions such as atherosclerosis, myocardial infarction, congestive heart failure, ischemic-reperfusion injury and other vascular inflammatory conditions.
• MAP-kinase related conditions can also include proliferative disorders, including cancers, e.g., multiple myeloma, fibrotic disorders, mesangial cell proliferative disorders, such as glomerulonephritis, diabetic nephropathy malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection and glomerulopathies.
• proliferative disorders including cancers, e.g., multiple myeloma, fibrotic disorders, mesangial cell proliferative disorders, such as glomerulonephritis, diabetic nephropathy malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection and glomerulopathies.
• MAP-kinase related condition can also include neurodegenerative diseases, e.g. Alzheimer's and pain sensation, as well as infectious diseases such as viral, bacterial, and fungal infections.
• compositions, kits, and methods of the present invention include those currently treated with soluble TNF receptors, anti-TNF antibodies, IL-I receptor antagonists, TNF- ⁇ converting enzyme inhibitors, inhibitors of protein-tyrosine kinases and/or inhibitors of protein serine/threonine kinases of the MAP kinase family, preferably including conditions currently treated with inhibitors of p38 MAP kinases and/or the stress-activated protein kinases/Jun N-terminal kinases
• conditions treatable with the practice of this invention include those relating to p38 ⁇ MAP kinase, e.g, conditions currently treated by inhibition of p38 ⁇ MAP kinase activity.
• Reducing the activity of a protein kinase e.g. a MAP kinase, is also referred to as “inhibiting” the kinase.
• the term “inhibits” and its grammatical conjugations, such as “inhibitory,” do not require complete inhibition, but refer to a reduction in kinase activity.
• Such reduction is preferably by at least about 50%, at least about 75%, at least about 90%, and more preferably by at least about 95% of the activity of the enzyme in the absence of the inhibitory effect, e.g., in the absence of an inhibitor.
• the phrase “does not inhibit” and its grammatical conjugations refer to situations where there is less than about 20%, less than about 10%, and preferably less than about 5%, of reduction in enzyme activity in the presence of the compound.
• does not substantially inhibit” and its grammatical conjugations refer to situations where there is less than about 30%, less than about 20%, and preferably less than about 10% of reduction in enzyme activity in the presence of the compound.
• the ability to reduce enzyme activity is a measure of the potency or the activity of a compound, or combination of compounds, towards or against the enzyme. Potency is preferably measured by cell free, whole cell and/or in vivo assays in terms of IC50, Kj and/or ED50 values.
• An IC50 value represents the concentration of a compound required to inhibit enzyme activity by half (50%) under a given set of conditions.
• a Kj value represents the equilibrium affinity constant for the binding of an inhibiting compound to the enzyme.
• An ED50 value represents the dose of a compound required to effect a half- maximal response in a biological assay. Further details of these measures will be appreciated by those of ordinary skill in the art, and can be found in standard texts on biochemistry, enzymology, and the like.
• Li some embodiments, compounds in one or more forms represented by formulas I, II, III, and IV inhibit a MAP kinase.
• These compounds can exert anti-inflammatory effects in vitro and/or in vivo and can form the basis for pharmaceutical compositions useful in the treatment of MAP kinase-related conditions, e.g., allergic, inflammatory and/or autoimmune diseases, in humans and other mammals.
• these compositions reduce production of, and signaling pathways involving, TNF-G! and IL- 1/3.
• a subset of the compounds of formulas I and II are novel analogs of known inhibitors of MAP kinases, wherein X comprises a lipophilic MAP kinase inhibitor or a lipophilic moiety or analog thereof.
• Some of these analogs retain MAP kinase inhibitory activity in the lactone and/or acid forms, and are useful in the practice of this invention, e.g. in a method of treating a MAP kinase-related condition by administering to a subject an effective amount of at least one of such compounds.
• certain lactone derivatives illustrated in Figure 5 are preferred in some embodiments, as described in detail above.
• a subset of the compounds of formulas I and II are novel analogs of known inhibitors of HMG-CoA reductase, wherein X comprises a lipophilic moiety of an HMG-CoA reductase inhibitor, e.g., a statin, a synthetic statin, or an analog thereof.
• HMG-CoA reductase inhibitor e.g., a statin, a synthetic statin, or an analog thereof.
• Some of these analogs display MAP kinase inhibitory activity in the lactone and/or acid forms, and are useful in the practice of this invention, e.g. in a method of treating a MAP kinase-related condition by administering to a subject an effective amount of at least one of such compounds.
• the acid forms of such compounds also display MAP kinase inhibitory activity.
• MAP kinase inhibition is not reversed by addition of farnesyl pyrophosphate, geranyl geranyl pyrophosphate, mevalonate or any downstream product of mevalonate.
• the lactone form does not inhibit or does not substantially inhibit HMG-CoA reductase.
• a lactone form may be formulated into solutions, suspensions, ointments and/or suppositories for topical application and/or rectal administration.
• the formulation maybe applied to regions of inflammation, e.g., to exert a local effect, as described in more detail below.
• regions of inflammation e.g., to exert a local effect, as described in more detail below.
• little or no systemic effects are observed
• Another subset of the compounds of formula I are known inhibitors of HMG- CoA reductase, including mevasatin, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin, rosuvastatin, pravastatin, glenvastatin, bervastatin, dalvastatin, eptastatin, dihydroeptastatin, itavastatin, L-154819, advicor, L-654969, and other statin drugs used to treat disorders such as hypercholesterolemia.
• the present invention relates to the use of the corresponding lactones of formula I in treating MAP kinase-related conditions, e.g., inflammatory diseases, in particular conditions where inhibiting p38 ⁇ MAP kinase activity is desirable and where a synthetic statin lactone is used.
• MAP kinase-related conditions e.g., inflammatory diseases, in particular conditions where inhibiting p38 ⁇ MAP kinase activity is desirable and where a synthetic statin lactone is used.
• such compounds find use in treating an inflammatory condition by administering an effective amount of a statin lactone to a subject where the lactone inhibits a MAP kinase.
• the statin lactones illustrated in Figure 6 are preferred in some embodiments for treating MAP kinase-related conditions.
• statin lactones are those derived from atorvastatin, fluvastatin, rosuvastatin, cerivastatin, pitavastatin and glenvastatin.
• MAP kinase inhibition is not reversed by addition of farnesyl pyrophosphate, geranyl geranyl pyrophosphate, mevalonate or any downstream product of mevalonate.
• the lactone is not hydrolyzed, or not substantially hydrolyzed, to an acid form, hi some such embodiments, the lactone does not inhibit or does not substantially inhibit HMG-CoA reductase.
• a lactone form may be formulated into solutions, suspensions, ointments and/or suppositories for topical application and/or rectal administration.
• the formulation may be applied to regions of inflammation, e.g., to exert a local effect, as described in more detail below.
• regions of inflammation e.g., to exert a local effect, as described in more detail below.
• the acid forms of such compounds also display MAP kinase inhibitory activity.
• Table I illustrates in vitro inhibition of p38 ⁇ MAP kinase activity by lactone derivatives of each of two classes of statins.
• atorvastatin and fluvastatin show inhibitory activity against human p38 ⁇ MAP kinase.
• Atrovastatin lactone gave an IC50 of about 20 ⁇ M, while fluvastatin lactone exhibited an IC50 value of about 45 ⁇ M in some embodiments.
• the acid/salt form of fluvastain e.g., fluvastatin sodium
• inhibits p38ce MAP kinase showing an IC50 of about 34 ⁇ M in some embodiments.
• lipophilic MAP kinase inhibitors as well as lipophilic moieties and analogs thereof, having structures that favor a closed ring structure or cyclic form, including compounds of formulas III and IV described above, can also display MAP kinase inhibitory activity.
• Structures comprising a lipophilic MAP kinase inhibitor or a lipophilic moiety thereof, for example the MAP kinase inhibitors of Figure 4, as well as lipophilic moieties or analogs thereof, such as those of Figure 5, are preferred in some embodiments.
• certain analogs of known lipophilic HMG-CoA reductase inhibitors having structures modified to favor a closed ring structure or cyclic form, including compounds of formulas III and IV described above, can also display MAP kinase inhibitory activity.
• Such structures can be useful in the practice of this invention, e.g., in a method of treating a MAP kinase-related condition by administering to a subject an effective amount of at least one of such compounds.
• a compound of formula III or IV does not inhibit or does not substantially inhibit HMG-CoA reductase.
• Structures comprising a statin or a lipophilic moiety of a statin, for example, the statins of Figure 6, as well as lipophilic moieties of statin analogs, such as those of Figures 7 and 8, are preferred in some embodiments. More preferred embodiments include des-oxo and ⁇ - lactam derivatives from a synthetic statin, or des-oxo and ⁇ -lactam derivatives from atorvastatin, fluvastatin rosuvastatin, cerivastatin, pitavastatin and glenvastatin, as described above.
• kits that can be used to treat a MAP kinase- related conditions.
• kits comprise a compound or combination of compounds described herein and preferably instructions teaching the use of the kit according to the various methods and approaches described herein.
• kits also include information, such as scientific literature references, package insert materials, clinical trial results, and/or summaries of these and the like, which indicate or establish the activities and/or advantages of the compound. Such information may be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials. Kits described herein can be provided, marketed and/or promoted to health providers, including physicians, nurses, pharmacists, formulary officials, and the like.
• HMG-CoA reductase-related condition refers to a condition in which directly or indirectly reducing the activity of HMG-CoA reductase is desirable and/or directly or indirectly reducing the production and/or effects of one or more products of HMG-CoA reductase is desirable.
• an HMG-CoA reductase-related condition may involve elevated levels of cholesterol, in particular, non- HDL cholesterol in plasma, such as elevated levels of LDL cholesterol.
• a patient is considered to have high or elevated cholesterol levels based on a number of criteria, for example, see Pearlman, Postgrad. Med. 112(2): 13-26 (2002), incorporated herein by reference. Guidelines include serum lipid profiles, such as LDL compared with HDL levels.
• HMG-CoA reductase-related conditions include hypercholesterolemia, lipid disorders such as hyperlipidemia, and atherogenesis and its sequelae of cardiovascular diseases, including atherosclerosis, other vascular inflammatory conditions, myocardial infarction, ischemic stroke, occlusive stroke, and peripheral vascular diseases, as well as other conditions in which decreasing cholesterol and/or other products of the cholesterol biosynthetic pathways can produce a benefit.
• Other HMG-CoA reductase-related conditions treatable with compositions, kits, and methods of the present invention include those currently treated with statins.
• Reducing the activity of HMG-CoA reductase is also referred to as "inhibiting" the enzyme.
• inhibitors and its grammatical conjugations, such as “inhibitory,” do not require complete inhibition, but refer to a reduction in HMG-CoA reductase activity. Such reduction is preferably by at least about 50%, at least about 75%, at least about 90%, and more preferably by at least about 95% of the activity of the enzyme in the absence of the inhibitory effect, e.g., in the absence of an inhibitor.
• the phrase “does not inhibit” and its grammatical conjugations refer to situations where there is less than about 20%, less than about 10%, and preferably less than about 5% of reduction in enzyme activity in the presence of the compound.
• the ability to reduce enzyme activity is a measure of the potency or the activity of the compound or combination of componds towards or against the enzyme. Potency is preferably measured by cell free, whole cell and/or in vivo assays in terms of IC50 or ED50 values.
• An IC50 value represents the concentration of a compound required to inhibit the enzyme activity by half (50%) under a given set of conditions.
• a Ki value represents the equilibrium affinity constant for the binding of an inhibiting compound to the enzyme.
• An ED50 value represents the dose of a compound required to effect a half- maximal response in a biological assay. Further details of these measures will be appreciated by those of ordinary skill in the art, and can be found in standard texts on biochemistry, enzymology, and the like.
• compounds in one or more forms represented by formulas I, II, III, and IV inhibit HMG-CoA reductase
• compounds of formula II inhibit HMG-CoA reductase.
• Such compounds find use in the practice of this invention e.g., in a method of treating an HMG-CoA reductase-related condition by administering to a subject an effective amount of at least one of such compounds.
• These compounds can lower cholesterol levels in vitro and in vivo, and/or increase HDL, thereby forming the basis for pharmaceutical compositions useful in the treatment of HMG-CoA reductase-related conditions, e.g., hypercholesterolemia and atherosclerosis, in humans and other mammals.
• a subset of the compounds of formulas I and II are novel analogs of known inhibitors of MAP kinases, wherein X comprises a lipophilic MAP kinase inhibitor or a lipophilic moiety or analog thereof.
• Some of these analogs display HMG-CoA reductase inhibitory activity, for example, in the acid form (formula EQ, and are useful in the practice of this invention, e.g., in a method of treating an HMG-CoA reductase-related condition by administering to a subject an effective amount of at least one of such compounds.
• Some of these analogs retain HMG-CoA reductase inhibitory activity in the lactone and/or acid form, in particular, in the acid carboxylate form, and are useful in the practice of this invention, e.g., in a method of treating an HMG-CoA reductase-related condition by administering to a subject an effective amount of at least one of such compounds.
• acid carboxylate forms of certain lactone derivatives illustrated in Figure 7 are preferred in some embodiments.
• a compound of the instant invention, or a composition comprising one or more such compounds can be used in treating an HMG-CoA reductase-related condition by increasing HDL levels.
• HDL levels are believed to protect against, e.g., atherosclerosis, whereas low HDL is recognized as an independent risk factor for cornary artery disease.
• an HDL level below about 40 mg/DL can be considered in need of treatment.
• compounds of the instant invention can bring about an upregulation of HDL in treating an HMG Co-A reductase related condition, such as artherosclerosis.
• Upregulating HDL is also referred to as "increasing" HDL or HDL levels.
• the term "increases" and its grammatical conjugations can refer to a small, significant and/or substantial increase, preferably an increase sufficient to decrease a risk of an HMG-CoA reductase-related condition in a subject being treated. Such increase is preferably by at least about 10%, at least about 20%, at least about 30%, and more preferably by at least about 50% of HDL levels in the absence of treatment.
• atorvastatin and analogs of atorvastatin are used to increase HDL.
• kits that can be used to treat an HMG-CoA reductase-related condition.
• kits comprise a compound or combination of compounds described herein, and preferably instructions teaching the use of the kit according to the various methods and approaches described herein.
• kits also include information, such as scientific literature references, package insert materials, clinical trial results, and/or summaries of these and the like, which indicate or establish the activities and/or advantages of the compound(s). Such information may be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials. Kits described herein can be provided, marketed and/or promoted to health providers, including physicians, nurses, pharmacists, formulary officials, and the like.
• One of the purposes of this invention is to describe compounds or combinations of compounds which inhibit both MAP kinase and HMG-CoA reductase.
• Such compounds or combinations can exert concomitant anti-inflammatory and cholesterol-lowering effects in vitro and/or in vivo, hi certain embodiments, for example, these compounds or combinations reduce production of, and signaling pathways involving, TNF- ⁇ and IL- 1/3, as well as inhibiting production of cholesterol and/or other downstream products of mevalonate, including mevalonate pyrophosphate, isopentyl pyrophosphate, geranyl pyrophosphate, farnesyl pyrophosphate, dolichols, farnesylated proteins, trans-trans geranylgeranyl pyrophosphate, ubiquinone, geranyl-geranylated proteins, squalene, and the like. Further, in some embodiments, these compounds or combinations can exert superior anti-atherogenesis and/or anti-inflammatory effects in vivo.
• compositions, kits, and methods for treating both MAP kinase-related conditions and HMG-CoA reductase-related conditions in humans and other animals can provide superior benefits in treating HMG-CoA reductase-related conditions, such as cardiovascular disease, compared with treatments that inhibit HMG- CoA reductase but do not inhibit or do not substantially inhibit MAP kinase.
• compositions of the present invention can provide superior benefits in treating MAP kinase-related conditions, such as inflammatory conditions, compared with treatments that inhibit MAP kinases but do not inhibit or do not substantially inhibit HMG-CoA reductase.
• Figure 10 illustrates a treatment approach in which compositions of the present invention produce a benefit in both MAP kinase- and HMG-CoA reductase- related conditions.
• This figure serves only as an example, and is in no way intended to be limiting with respect to the present invention.
• those skilled in the art will readily appreciate variations and modifications of the scheme illustrated, and such variations and modifications are also contemplated as being contained within the scope of the invention.
• the ⁇ -lactone form (formula I) of a compound of this invention can inhibit a MAP kinase, and the acid form (formula II), in particular the deprotonated carboxylate form (formula lib), can inhibit HMG-CoA reductase.
• this treatment approach can provide a benefit in both a HMG-CoA reductase-related condition and a MAP kinase-related condition, for instance, in a method comprising administering to a subject an effective amount of at least one of such compounds, e.g., reducing pro-inflammatory cytokine production, in the treatment of a MAP kinase-related condition, such as an allergic, inflammatory and/or autoimmune condition, and reducing cholesterol production in the treatment of a HMG-CoA reductase- related condition, such as cardiovascular disease.
• a MAP kinase-related condition such as an allergic, inflammatory and/or autoimmune condition
• cholesterol production in the treatment of a HMG-CoA reductase- related condition, such as cardiovascular disease.
• This reduction in pro-inflammatory cytokine production by inhibition of a MAP kinase may be in addition to other immunomodulatory effects of some HMG-CoA reductase inhibitors that may, for example, produce immunomodulatory responses though the action of metabolites such as farnesyl pyrophosphate and/or geranylgeranyl pyrophosphate.
• HMG-CoA reductase inhibitors may, for example, produce immunomodulatory responses though the action of metabolites such as farnesyl pyrophosphate and/or geranylgeranyl pyrophosphate.
• the role of a compound of the present invention in a MAP kinase-related pathway is distinct from the anti-inflammatory effects of some statins through metabolite products such as geranylgeranyl pyrophosphate and/or farnesyl pyrophosphate.
• the inhibitory activity of some compounds of this invention on a MAP kinase and on MAP-kinase related conditions need not be reversed by exogenous addition of mevalonate (e.g., sodium mevalonate), geranylgeranyl pyrophosphate, farnesyl pyrophosphate, and/or other downstream product of mevalonate.
• mevalonate e.g., sodium mevalonate
• geranylgeranyl pyrophosphate e.g., farnesyl pyrophosphate
• other downstream product of mevalonate e.g., mevalonate
• mevalonate e.g., sodium mevalonate
• geranylgeranyl pyrophosphate e.g., farnesyl pyrophosphate
• other downstream product of mevalonate e.g., mevalonate
• the interplay between inflammatory and HMG-CoA reductase- related disorders means that compositions regulating both
• HMG-CoA reductase can lead to improved serum lipid profiles, such as decreased LDL and increased HDL levels, which in turn can lead to a reduction in the rate of atherogenesis.
• initiation of atherogenic plaque deposition e.g., via foam cells
• is reduced by the anti-inflammatory effects including those which derive from inhibition of a MAP kinase.
• Inhibition of a MAP kinase can also antagonize inflammatory processes which contribute to the disruption of atherogenic plaques and which, in turn, can lead to arterial thrombosis, blockade, etc.
• compositions including a compound of formula I/II and having inhibitory activity against both a MAP kinase and HMG-CoA reductase can be superior, preferably differentially superior, to drugs targeting only HMG- CoA reductase.
• such compositions can provide a differentially superior benefit in treating cardiovascular disease related to atherogenesis, including formation and disruption of atherosclerotic plaques.
• compositions including a compound or combination of compounds of formula I and/or formula II having inhibitory activity against both a MAP kinase and HMG-CoA reductase can be superior, preferably differentially superior, to drugs targeting only a MAP kinase in terms of treating a MAP kinase-related condition, such as inflammation, again due to the interplay between inflammatory and cardiovascular conditions.
• a compound of formula I inhibits or is more potent against a MAP kinase while the corresponding compound of formula II, with equivalent X, Y, Z, A and stereochemistry, inhibits or is more potent against HMG-CoA reductase.
• the activities or potencies of a compound of formula I and the corresponding compound of formula II are similar towards a MAP kinase and HMG-CoA reductase.
• the potencies of these forms against their respective targets differs by no more than a factor of about 1000, more preferably about 100, and most preferably about 10.
• compounds of formulas I and II have absolute configuration as illustrated in Figure 3b and designated as (T 1 T) absolute configuration, as defined above.
• the potency of a compound of formula I and/or II against a MAP kinase is greater than its potency against HMG-CoA reductase.
• potencies with respect to a MAP kinase and HMG-CoA reductase differ by at least a factor of about 10. More preferably, potencies can differ by more than a factor of about 100. Most preferably, potencies can differ by more than a factor of about 1000.
• a compound of formula I inhibits both a MAP kinase and HMG-CoA reductase.
• a compound of formula II inhibits both a MAP kinase and HMG-CoA reductase.
• a compound of formula II inhibits both a MAP kinase and HMG-CoA reductase.
• a compound of formula IV inhibits both a MAP kinase and HMG-CoA reductase.
• compounds of formula II inhibit HMG-CoA reductase.
• a MAP kinase analog of the present invention inhibits a MAP kinase in the lactone form of formula I and inhibits HMG-CoA reductase in the corresponding acid form of formula ⁇ , in particular the carboxylate form of formula lib.
• such compounds are useful in the present invention, e.g., in a method comprising administering to a subject an effective amount of at least one of such compounds to treat a MAP kinase-related condition and additionally treating an HMG-CoA reductase-related condition.
• MAP kinase analogs illustrated in Figure 5 can provide examples of such preferred embodiments, hi other embodiments, the lactone form inhibits both a MAP kinase and HMG-CoA reductase; in still other embodiments, the acid form inhibits both a MAP kinase and HMG-CoA reductase.
• X comprises a lipophilic moiety of an HMG-CoA reductase inhibitor, e.g., a statin, a synthetic statin, or an analog thereof.
• HMG-CoA reductase inhibitor e.g., a statin, a synthetic statin, or an analog thereof.
• a statin analog of the present invention inhibits HMG-CoA reductase in the acid form of formula II (in particular, in the carboxylate form of formula lib) and inhibits a MAP kinase in the corresponding lactone form of formula I.
• such compounds find use in the practice of the invention, e.g., in a method comprising administering to a subject an effective amount of at least one of such compounds to treat a MAP kinase-related condition and additionally treating an HMG-CoA reductase-related condition.
• Statin analogs illustrated in Figure 7 can provide examples of such preferred embodiments, and the specific examples illustrated in Figure 8 can provide even more preferred embodiments.
• kits that can be used to treat MAP kinase- and HMG-CoA reductase-related conditions, in particular cardiovascular disease related to atherogenesis.
• kits can comprise a compound or combination of compounds described herein, including compounds of formula I and/or II which have inhibitory activity against both a MAP kinase and HMG-CoA reductase, and preferably instructions teaching the use of the kit according to the various methods and approaches described herein.
• kits also include information, such as scientific literature references, package insert materials, clinical trial results, and/or summaries of these, and the like, which indicate or establish the multiple activities of the compounds or combination and indicate and/or establish how its use provides advantages and/or differential superiority in treating an HMG-CoA reductase- and/or a MAP kinase-related condition, preferably in treating cardiovascular disease.
• Such information may be based on the results of various studies, for example, studies using experimental animals involving in vivo models and studies based on human clinical trials.
• Kits of the present invention may also include materials comparing the approaches of the present invention with other therapies, which do not display a combination of MAP kinase plus HMG-CoA reductase inhibitory activities. Kits described herein can be provided, marketed and/or promoted to health providers, including physicians, nurses, pharmacists, formulary officials, and the like. D. Treatment of Inflammatoiy Conditions
• Another aspect of the present invention relates to methods of using pharmaceutical compositions and kits comprising combinations of compounds, forms and/or agents described herein to treat MAP kinase-related and/or HMG-CoA reductase- related conditions that are inflammatory conditons.
• Inflammatory conditions can refer to inflammatory diseases or disorders associated with inflammation due to relatedness to MAP kinase-, HMG CoA reductase- and/or other pathways.
• Inflammatory conditions treatable using some embodiments of the instant invention can involve different organ systems, and can vary in severity from trivial to lethal.
• inflammatory conditions of the skin can be treated in some embodiments of the instant invention, including, but not limited to, atopic dermatitis, age- related effects, acne, eczema, psoriasis and skin cancer.
• acne can be treated uisng some embodiments of the instant invention, including, e.g., acne atrophica, bromide or chlorine acne, common acne (acne vulgaris), acne conglobata, contact acne, contagious acne of horses, acne cosmetica, cystic acne, acne detergicans, epidemic acne, acne estivalis, excoriated acne, acne frontalis, acne fulminans, halogen acne, acne indurata, infantile acne, iodide acne, acne keloid, acne mechanica, acne necrotica miliaris, neonatal acne, acne papulosa, picker's acne, pommade acne, premenstrual acne, acne pustulosa, acne rosacea, acne scorbutica, acne scrofulosorum, acne tropicalis, acne urticata, acne varioliformis, acne venenata, and the like.
• acne atrophica bromide or chlorine acne
• common acne acne vulgaris
• acne conglobata contact
• eczema can be treated in some embodiments of the instant invention, including, e.g., eczematous dermatitis, such as atopic dermatitis, the most common form of eczema, generally seen in infants and young adults. Eczema can present as a red, itchy, non-contagious inflammation of the skin that can be acute or chronic, possibly accompanied by red skin patches, pimples, crusts, scabs, and watery discharge.
• Various effects of ageing can be treated in some embodiments of the instant invention, including, e.g., skin-related inflammatory diseases attributable to ageing.
• Such effects can include formation of wrinkles and fine lines, slackening of cutaneous and subcutaneous tissue, loss of skin elasticity, reduction in skin tone and texture and/or yellowing.
• Loss of elasticity can result form atrophy of the epidermis, beginning on a small scale and eventually decreasing the number of cells in the dermis.
• Capillaries can become more susceptible to bruising, collagen metabolism may slow, and/or the concentration of the cell surface molecule glycosaminoglycan (believed to have a role in the recognition of other cells and substrates) may decrease. With ageing, skin may exhibit chronic inflammation with enlarged fibroblasts.
• Effects of ageing aggravated with sun exposuse can also be treated in some embodiments, e.g., pigmentation marks, telangiectasias, elastosis, and/or other skin photo-damage, as well as benign, premalignant and/or malignant neoplasms (e.g., caused by prolonged sun exposure).
• Ageing itself e.g., can be considered as an inflammatory condition, e.g., as the ability to mount an inflammatory response decreases and healing time for injuries increases with age.
• Inflammatory conditions of the skin that can be treated in some embodiments of the instant invention include skin cancers and other hyperproliferative skin disorders, including, e.g., without being not limited to, basal cell carcinoma, squamous cell carcinoma (Bowen's disease), keratosis (such as actinic or seborrheic keratosis), and/or disorders of keratinization (such as ichthyosis and keratoderma).
• basal cell carcinoma squamous cell carcinoma (Bowen's disease)
• keratosis such as actinic or seborrheic keratosis
• disorders of keratinization such as ichthyosis and keratoderma.
• Inflammatory conditions of the respiratory system can be treated in some embodiments of the instant invention, including, but not limited to, allergic rhinitis, chronic obstructive pulmonary disease, adult respiratory distresss syndrome, asthma, and the like.
• Allergic asthma can include atopic, chronic diseases of the lung characterized by inflammation of the air passages.
• Allergic rhinitis or hay fever can include conditions that affect mucous membranes characterized by seasonal or perennial nasal inflammation, e.g., in response to an allergen.
• Other mucous inflammatory conditions treatable using some embodiments of the instant invention can include lamellar ichthyosis, acne, rosacea, and the like.
• Inflammatory conditions of the urogenital tract can be treated in some embodiments of the instant invention, including, but not limited to, vaginitis and interstitial cystitis, and other conditions characterized by inflammation of the urogenital epithelium and/or the urinary bladder.
• Interstitial cystitis also can include other conditions associated with a dysfunctional bladder glycosaminoglycan protective layer and/or increased numbers of activated bladder mast cells.
• Inflammatory conditions of the gastrointestinal tract can be treated in some embodiments of the instant invention, including, but not limited to, celiac diseases, e.g., celiac sprue, inflammatory bowel disease (including ulcerative colitis and Crohn's disease), intestinal infections, enterocolitis, gastritis, and the like.
• celiac diseases e.g., celiac sprue
• inflammatory bowel disease including ulcerative colitis and Crohn's disease
• intestinal infections e.g., enterocolitis, gastritis, and the like.
• Inflammatory conditons of the musculoskeletal system can be treated in some embodiments of the instant invention, including, but not limited to, inflammatory muscle pain, arthritis, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, osteoporosis, and the like.
• Osteoporosis can include conditions characterized by decreased bone mass, increased fragility of the remaining bone, and/or increased incidence of fractures.
• Inflammatory conditions of the vascular system an be treated in some embodiments of the instant invention, including, but not limited to hypercholesterolemia, hyperlipidemia, atherogenesis and associated cardiovascular risks of atherosclerosis, thrombosis, myocardial infarction, ischemic stroke, ischemic-reperfusion injury, peripheral vascular disease, e.g., peripheral occlusive disease, and the like.
• Inflammatory conditions of the systemic circulation also include endotoxemia, lupus erythrematosus, sepsis, toxic shock syndrome and transplant rejection, and may also be treated in some embodiments.
• compositions comprisng combinations of compunds, forms and/or agents described herein provide treatments for autoimmune conditions.
• Autoimmune conditions as used herein can include organ or tissue-specific autoimmune conditions, as well as those which affect the whole body.
• Organ or tissue-specific autoimmune conditions that can be treated in some embodiments of the instant invention include, e.g., type I diabetes mellitus, multiple sclerosis, primary billiary cirrhosis, Hashimotos thyroiditis, pernicious anemia, Crohn's disease, Addison's disease, myasthenia gravis, rheumatoid arthritis, uveitis, psoriasis, Guillain-Barre Syndrome, Graves' disease, and the like.
• Systemic autoimmune conditions that can be treated in some embodiments include, e.g., systemic lupus erythematosus, ermatomyositis, and the like.
• combinations comprising a statin lactone and one or more additional active agents can be used in treating one or more of the inflammatory conditions provided herein.
• Preferred combinations can depend on the affected system.
• combinations comprising a statin lactone and a salt form of a hydroxy acid statin are preferred in the treatment of inflammatory conditions of the vascular system and central nervous system, especially Alzheimer's disease, as well as inflammatory conditions of the skin, especially eczema, psoriasis, acne and the effects of ageing.
• preferred combinations comprise atorvastatin lactone with a salt of either atorvastatin or pitavastatin in a molar ratio of about 90:10 to about 10:90.
• combinations comprising a statin lactone and a non-statin anti- inflammatory agent are preferred, e.g., where combinations comprising atorvastatin lactone and a non-steroidal anti-inflammatory drug are used in a molar ratio of about 90:10 to about 10:90.
• One of the purposes of this invention is to teach combinations of compounds that can produde synergistic effects in treating an inflammatory condition, e.g., one or more of the inflammatory conditions provided herein.
• a combination of a statin lactone and another active agent provides a synergistic effect in treating an inflammatory condition, as detailed above. Additional details of combinations providing synergistic inhibitory effects in treating inflammation are provided in Example 8 below.
• Yet another aspect of the present invention relates to formulations, routes of administration and effective doses for pharmaceutical compositions comprising a compound or combination of compounds of the instant invention.
• Such pharmaceutical compositions can be used to treat inflammatory, MAP kinase-related, and/or HMG-CoA reductase-related conditions, as described in detail above.
• the compounds of formula I/II may be provided in a either the lactone or acid form, and/or may be allowed to interconvert in vivo after administration. That is, either the ⁇ -lactone or hydroxy carboxylic acid form, or pharmaceutically acceptable salts, esters or amides thereof, may be used in developing a formulation for use in the present invention. Further, in some embodiments, the compound may be used in combination with one or more other compounds or with one or more other forms. For example a formulation may comprise both the lactone and acid forms in particular proportions, depending on the relative potencies of the lactone and acid forms and the intended indication.
• compositions for treating both MAP kinase- and HMG-CoA reductase-related conditions where the lactone form inhibits MAP kinase and the acid (carboxylate) form inhibits HMG-CoA reductase, and where potencies are similar about a 1 : 1 ratio of lactone to acid forms may be used.
• the two forms may be formulated together, in the same dosage unit e.g.
• each form may be formulated in a separate unit, e.g., two creams, two suppositories, two tablets, two capsules, a tablet and a liquid for dissolving the tablet, a packet of powder and a liquid for dissolving the powder, etc.
• compounds of formula III and IV may be used alone, together, or in combination with the corresponding or other compounds of formula I and II, described above.
• a compound of formula IV (closed ⁇ -lactam ring) may be co-administered with a compound of formula II (open acid form), where the compounds have equivalent X, Y, Z, A and stereochemistries.
• Such administration may be useful for treating both MAP kinase- and HMG-CoA reductase-related conditions, for example, where the lactam form inhibits MAP kinase and the acid (carboxylate) form inhibits HMG-CoA reductase.
• the two forms may be formulated together, in the same dosage unit e.g. in one cream, suppository, tablet, capsule, or packet of powder to be dissolved in a beverage; or each form may be formulated in separate units, e.g, two creams, suppositories, tablets, two capsules, a tablet and a liquid for dissolving the tablet, a packet of powder and a liquid for dissolving the powder, etc.
• Typical salts are those of the inorganic ions, such as, for example, sodium, potassium, calcium, magnesium ions, and the like.
• Such salts include salts with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, mandelic acid, malic acid, citric acid, tartaric acid or maleic acid.
• suitable bases include sodium hydroxide, potassium hydroxide, ammonia, cyclohexylamine, dicyclohexyl-amine, ethanolamine, diethanolamine, triethanolamine, and the like.
• a pharmaceutically acceptable ester or amide refers to those which retain biological effectiveness and properties of the compounds used in the present invention, and which are not biologically or otherwise undesirable.
• the ester or amide does not interfere with the beneficial effect of a compound of the invention in inhibiting MAP kinase and/or HMG-CoA reductase, e.g., in treating an inflamatory, MAP kinase- related and/or HMG-CoA reductase related conditon.
• Typical esters include ethyl, methyl, isobutyl, ethylene glycol, and the like.
• Typical amides include unsubstituted amides, alkyl amides, dialkyl amides, and the like.
• a compound may be administered in combination with one or more other compounds, forms, and/or agents, e.g., as described above.
• compositions comprising combinations of a statin lactone with one or more other active agents can be formulated to comprise certain molar ratios.
• molar ratios of about 99:1 to about 1:99 of statin lactone to the other active agent can be used.
• the range of molar ratios of statin lactone: other active agent is selected from about 80:20 to about 20:80; about 75:25 to about 25:75, about 70:30 to about 30:70, about 66:33 to about 33:66, about 60:40 to about 40:60; about 50:50; and about 90:10 to about 10:90.
• the molar ratio of statin lactone: other active agent is about 1:9, and most preferably about 1:1.
• the two compounds, forms and/or agents may be formulated together, in the same dosage unit e.g. in one cream, suppository, tablet, capsule, or packet of powder to be dissolved in a beverage; or each compound, form, and/or agent may be formulated in separate units, e.g, two creams, suppositories, tablets, two capsules, a tablet and a liquid for dissolving the tablet, a packet of powder and a liquid for dissolving the powder, etc.
• the compounds and/or combinations of compounds may be administered with still other agents.
• the choice of agents that can be co-administered with the compounds and/or combinations of compounds of the instant invention can depend, at least in part, on the condition being treated.
• Agents of particular use in the formulations of the present invention include, for example, any agent having a therapeutic effect for kinase-related and/or HMG-CoA reductase-related conditions, including, e.g., drugs used to treat inflammatory conditions.
• formulations of the instant invention may additionally contain one or more conventional acne treatments, such as keratolytic agents, e.g., retinoids, particularly retinoic acid; anti-inflammatory agents, such as peroxides, particularly benzoyl peroxide; and antiseborrhoeic agents.
• formulations may additionally contain one or more supplements, such as vitamin D and/or calcium, and/or one or more biphosphonate medications, e.g., which block bone resorption.
• supplements such as vitamin D and/or calcium
• biphosphonate medications e.g., which block bone resorption.
• compounds and/or combinations of compounds described herein can be co-formulated and/or co-administered with agents useful for the prevention and/or treatment of atherosclerosis and its sequelae.
• agents include, but are not limited to, e.g., inhibitors of cholesterol ester transferase protein (CETP) (e.g., JTT-705, torcetrapib); inhibitors of sterol acyl-CoA-acyl transferase (ACAT) (e.g., pactimibe, SMP-797, K-604); inhibitors of microsomal triglyceride transferase protein (MTTP) (e.g., implitipide, JTT-130); modulators of peroxisome proliferators activated receptors (PPARs) (e.g., binifibrate, gemfibrozil, clinofibrate, ronifibrate, fenofibrate, bezafibrate, LY-929, GW-516, GW-590735, NS-220, LY-674, DRF-10945, SB-641597, AVE-8134, AVE-0847, ciglitazone, pi
• the compound(s) may be administered per se or in the form of a pharmaceutical composition wherein the active compound(s) is in an admixture or mixture with one or more pharmaceutically acceptable carriers.
• a pharmaceutical composition as used herein, may be any composition prepared for administration to a subject.
• Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers, comprising excipients, diluents, and/or auxiliaries, e.g., which facilitate processing of the active compounds into preparations that can be administered. Proper fonnulation may depend at least in part upon the route of administration chosen.
• the compound(s) useful in the present invention can be delivered to a patient using a number of routes or modes of administration, including oral, buccal, topical, rectal, transdermal, transmucosal, subcutaneous, intravenous, and intramuscular applications, as well as by inhalation.
• routes or modes of administration including oral, buccal, topical, rectal, transdermal, transmucosal, subcutaneous, intravenous, and intramuscular applications, as well as by inhalation.
• the compounds can be formulated readily by combining the active compound(s) with pharmaceutically acceptable carriers well known in the art.
• Such carriers enable the compounds of the invention to be formulated as tablets, including chewable tablets, pills, dragees, capsules, lozenges, hard candy, liquids, gels, syrups, slurries, powders, suspensions, elixirs, wafers, and the like, for oral ingestion by a patient to be treated.
• Such formulations can comprise pharmaceutically acceptable carriers including solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents.
• the compounds of the invention will be included at concentration levels ranging from about 0.5%, about 5%, about 10%, about 20%, or about 30% to about 50%, about 60%, about 70%, about 80% or about 90% by weight of the total composition of oral dosage forms, in an amount sufficient to provide a desired unit of dosage.
• Aqueous suspensions for oral use may contain compound(s) of this invention with pharmaceutically acceptable excipients, such as a suspending agent (e.g., methyl cellulose), a wetting agent (e.g., lecithin, lysolecithin and/or a long-chain fatty alcohol), as well as coloring agents, preservatives, flavoring agents, and the like.
• a suspending agent e.g., methyl cellulose
• a wetting agent e.g., lecithin, lysolecithin and/or a long-chain fatty alcohol
• oils or non-aqueous solvents may be required to bring the compounds into solution, due to, for example, the presence of large lipophilic moieties.
• emulsions, suspensions, or other preparations for example, liposomal preparations, may be used.
• liposomal preparations any known methods for preparing liposomes for treatment of a condition may be used. See, for example, Bangham et al., J. MoI. Biol. 23: 238-252 (1965) and Szoka et al, Proc. Natl Acad. Sd. USA 75: 4194-4198 (1978), incorporated herein by reference.
• Ligands may also be attached to the liposomes to direct these compositions to particular sites of action.
• Compounds of this invention may also be integrated into foodstuffs, e.g, cream cheese, butter, salad dressing, or ice cream to facilitate solubilization, administration, and/or compliance in certain patient populations.
• foodstuffs e.g, cream cheese, butter, salad dressing, or ice cream to facilitate solubilization, administration, and/or compliance in certain patient populations.
• compositions for oral use can be obtained as a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
• suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; flavoring elements, cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone (PVP).
• disintegrating agents maybe added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
• the compounds may also be formulated as a sustained release preparation.
• Dragee cores can be provided with suitable coatings.
• suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
• Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compounds.
• Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
• the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
• the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols, hi addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for administration. [00272] In some preferred embodiments, oral formulations are used to treat Alzheimer's and/or other inflammatory conditons of the central nervous system.
• oral formulations are used to treat arthritis, rheumatoid arthritis and/or other inflammatory conditions of the musculoskeletal system.
• preferred compositions in such embodiments are those comprising a statin lactone and a non-statin anti-inflammatory agent.
• oral formulations are used to treat inflammatory conditions of the vascular system especially hypercholesterolemia, hyperlipidemia, atherosclerosis, peripheral occlusive disease, myocardial infarction, and stroke.
• Preferred compositions in such embodiments are those comprising a statin lactone and a salt form of a hydroxy acid statin. More preferred are combinations of atorvastatin lactone with a salt of either atorvastatin or pitavastatin, even more preferably in a molar ratio of about 90:10 to about 10:90. Additional details of such preferred embodiments for oral formulations are provided in Example 4, as outlined above.
• Example 4b describes a coated tablet formulation comprising atorvastatin lactone and atorvastatin calcium, at a ratio of 1 : 1.
• Example 4c describes a coated tablet formulation of enteric- coated granules comprising atorvastatin lactone and pitavastatin calcium, at a ratio of 1 : 1.
• the compounds of the present invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
• physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer.
• Such compositions may also include one or more excipients, for example, preservatives, solubilizers, fillers, lubricants, stabilizers, albumin, and the like.
• excipients for example, preservatives, solubilizers, fillers, lubricants, stabilizers, albumin, and the like.
• Methods of formulation are known in the art, for example, as disclosed in Remington's Pharmaceutical Sciences, latest edition, Mack Publishing Co., Easton P. [00275]
• the compounds may also be formulated as a depot preparation.
• compositions comprising one or more compounds of the present invention exert local and regional anti-inflammatory effects when administered topically or injected at or near particular sites of inflammation.
• Direct topical application e.g., of a viscous liquid, gel, jelly, cream, lotion, ointment, suppository, foam, or aerosol spray
• Pharmaceutically appropriate vehicles for such formulation include, for example, lower aliphatic alcohols, polyglycols (e.g., glycerol or polyethylene glycol), esters of fatty acids, oils, fats, silicones, and the like.
• Such preparations may also include preservatives (e.g., p-hydroxybenzoic acid esters) and/or antioxidants (e.g., ascorbic acid and tocopherol).
• compositions in such embodiments are those comprising atorvastatin lactone and a non-steroidal anti- inflammatory drug, even more preferably in a molar ratio of about 90:10 to about 10:90.
• local/topical formulations are used to treat allergic, inflammatory and/or autoimmune conditions of the skin or skin structures, especially for treating eczema, psoriasis, acne and the effects of aging.
• a cream comprising a compound of the invention in formula I, II, III, or IY may be topically applied to the affected site, for example, sites displaying red plaques or dry scales in psoriasis, or areas of irritation and dryness in dermatitis.
• Preferred compositions in such embodiments are those comprising a statin lactone and a salt form of a hydroxy acid statin. More preferred are combinations of atorvastatin lactone with a salt of either atorvastatin or pitavastatin, even more preferably in a molar ratio of about 90:10 to about 10:90.
• compositions of the present invention may contain a cosmetically or dermatologically acceptable carrier.
• Such carriers are compatible with skin, nails, mucous membranes, tissues and/or hair, and can include any conventionally used cosmetic or dermatological carrier meeting these requirements.
• Such carriers can be readily selected by one of ordinary skill in the art.
• a compound or combination of compounds of the instant invention may be formulated in an oleaginous hydrocarbon base, an anhydrous absorption base, a water-in-oil absorption base, an oil-in-water water-removable base and/or a water-soluble base.
• compositions according to the present invention may be in any form suitable for topical application, including aqueous, aqueous-alcoholic or oily solutions, lotion or serum dispersions, aqueous, anhydrous or oily gels, emulsions obtained by dispersion of a fatty phase in an aqueous phase (O/W or oil in water) or, conversely, (W/O or water in oil), microemulsions or alternatively microcapsules, microparticles or lipid vesicle dispersions of ionic and/or nonionic type.
• These compositions can be prepared according to conventional methods.
• the amounts of the various constituents of the compositions according to the invention are those conventionally used in the art.
• compositions in particular constitute protection, treatment or care creams, milks, lotions, gels or foams for the face, for the hands, for the body and/or for the mucous membranes, or for cleansing the skin.
• compositions may also consist of solid preparations constituting soaps or cleansing bars.
• compositions of the present invention may also contain adjuvants common to the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, sunscreens, odor-absorbers and dyestuffs.
• adjuvants common to the cosmetic and dermatological fields, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preserving agents, antioxidants, solvents, fragrances, fillers, sunscreens, odor-absorbers and dyestuffs.
• the amounts of these various adjuvants are those conventionally used in the fields considered and, for example, are from about 0.01% to about 20% of the total weight of the composition.
• these adjuvants may be introduced into the fatty phase, into the aqueous phase and/or into the lipid vesicles.
• Example 4a describes a gel formulation comprising atorvastatin lactone and atorvastatin calcium.
• Example 4d describes a hydrophilic ointment comprising atorvastatin lactone and naproxen sodium.
• Example 4e describes a polyethylene glycol ointment comprising atorvastatin lactone and diclofenac.
• Example 4g describes an ointment comprising atorvastatin lactone and indomethacin.
• Example 4h describes a gel formulation including atorvastatin lactone and indomethacin.
• Example 4i describes a cream formulation comprising atorvastatin lactone and indomethacin.
• Example 4j describes a skin ointment comprising atorvastatin lactone and petrolatum USP.
• Example 4k describes a skin ointment comprising fluvastatin lactone and white petrolatum.
• Example 41 describes a skin ointment comprising cerivastatin lactone.
• Example 4m describes a skin ointment comprising pravastatin lactone and polyethylene glycol, hi more preferred embodiments, the ointment, gel, and/or cream formulations described in Examples 4g, 4h, and 4i, respectively, provide synergistic inhibitory effects in treating inflammation, e.g., as detailed in Example 8 below.
• ocular allergic, inflammatory and/or autoimmune conditions can be effectively treated with ophthalmic solutions, suspensions, ointments or inserts comprising a compound or combination of compounds of the present invention.
• Preferred embodiments of formulations for ocular use are provided in Example 4. Specifically, Example 4n describes an isotonic solution comprising rosuvastatin; Example 4o describes an ointment comprising cerivastatin lactone; and Example 4p describes an ointment comprising atorvastatin lactone, each of which can be used for ocular application.
• allergic, inflammatory and/or autoimmune conditions of the ear can be effectively treated with otic solutions, suspensions, ointments or inserts comprising a compound or combination of compounds of the present invention.
• Preferred embodiments of formulations for otic use are provided in Example 4. Specifically, Example 4q describes a solution comprising fluvastatin sodium and glycerin for otic use.
• the compounds of the present invention are delivered in soluble rather than suspension form, which allows for more rapid and quantitative absorption to the sites of action, hi general, formulations such as jellies, creams, lotions, suppositories and ointments can provide an area with more extended exposure to the compounds of the present invention, while formulations in solution, e.g., sprays, provide more immediate, short-term exposure.
• the pharmaceutical compositions can include one or more penetration enhancers.
• the formulations may comprise suitable solid or gel phase carriers or excipients that increase penetration or help delivery of compounds or combinations of compounds of the invention across a permeability barrier, e.g., the skin.
• penetration-enhancing compounds include, e.g., water, alcohols (e.g., terpenes like methanol, ethanol, 2-propanol), sulfoxides (e.g., dimethyl sulfoxide, decylmethyl sulfoxide, tetradecylmethyl sulfoxide), pyrrolidones (e.g., 2- ⁇ yrrolidone, N- methyl-2-pyrrolidone, N-(2-hydroxyethyl)pyrrolidone), laurocapram, acetone, dimethylacetamide, dimethylformamide, tetrahydrofurfuryl alcohol, L- ⁇ -amino acids, anionic, cationic, amphoteric or nonionic surfactants (e.g., isopropyl myristate and sodium lauryl sulfate), fatty acids, fatty alcohols (e.g., oleic acid),
• alcohols e.g., terpen
• the pharmaceutical compositions for local/topical application can include one or more antimicrobial preservatives such as quaternary ammonium compounds, organic mercurials, ⁇ -hydroxy benzoates, aromatic alcohols, chlorobutanol, and the like.
• antimicrobial preservatives such as quaternary ammonium compounds, organic mercurials, ⁇ -hydroxy benzoates, aromatic alcohols, chlorobutanol, and the like.
• Gastrointestinal allergic, inflammatory and/or autoimmune conditions can be effectively treated with orally- or rectally delivered solutions, suspensions, ointments, enemas and/or suppositories comprising a compound or combination of compounds of the present invention.
• Local/topical formulations are preferred for therapy of Crohn's colitis and other allergic, inflammatory and/or autoimmune diseases of the gastrointestinal system.
• a suppository formulation of a compound or combination of compounds disclosed herein can be used.
• the active ingredient can produce a benefit locally at or near the site of application, rather than systemically, by inhibiting a MAP kinase inhibitor, e.g., p38 ⁇ MAP kinase.
• a lactone form (formula I) of a known statin is used in formulations for topical inhibition of MAP kinase.
• the statin lactone used topically is a synthetic statin lactone, such as atorvastatin, cerivastatin, fluvastatin, pitavastatin, glenvastatin, and/or rosuvastatin, including, for example, structures provided in Figures 7 and 8.
• compounds modified to favor a closed ring structure such as formulas III and rV of Figure 9, are used in formulations for topical inhibition of MAP kinase.
• the modified compound is derived from a synthetic statin lactone, such as atorvastatin, cerivastatin, fluvastatin, pitavastatin, glenvastatin, and/or rosuvastatin.
• Example 4r describes a retention enema comprising cerivastatin sodium
• Example 4s describes a retention enema comprising pitavastatin lactone
• Example 4t describes a rectal suppository comprising fluvastatin lactone
• Example 4u describes a rectal suppository comprising atorvastatin lactone
• Example 4f describes a rectal suppository comprising atorvastatin lactone and aminosalicylic acid.
• Respiratory allergic, inflammatory and/or autoimmune conditions can be effectively treated with aerosol solutions, suspensions or dry powders comprising a compound or combination of compounds of the present invention.
• Administration by inhalation is particularly useful in treating inflammatory conditions of the lung.
• the aerosol can be administered through the respiratory system or nasal passages.
• a composition of the present invention can be suspended or dissolved in an appropriate carrier, e.g., a pharmaceutically acceptable propellant, and administered directly into the lungs using a nasal spray or inhalant.
• an aerosol formulation comprising a MAP kinase and/or HMG CoA reductase inhibitor can be dissolved, suspended or emulsified in a propellant or a mixture of solvent and propellant, e.g., for administration as a nasal spray or inhalant.
• Aerosol formulations may contain any acceptable propellant under pressure, preferably a cosmetically or dermatologically or pharmaceutically acceptable propellant, as conventionally used in the art.
• An aerosol formulation for nasal administration is generally an aqueous solution designed to be administered to the nasal passages in drops or sprays.
• Nasal solutions can be similar to nasal secretions in that they are generally isotonic and slightly buffered to maintain apH of about 5.5 to about 6.5, although pH values outside of this range can additionally be used.
• Antimicrobial agents or preservatives can also be included in the formulation.
• An aerosol formulation for inhalations and inhalants can be designed so that the compound or combination of compounds of the present invention is carried into the respiratory tree of the subject when administered by the nasal or oral respiratory route.
• Inhalation solutions can be administered, for example, by a nebulizer.
• Inhalations or insufflations, comprising finely powdered or liquid drags, can be delivered to the respiratory system as a pharmaceutical aerosol of a solution or suspension of the compound or combination of compounds in a propellant, e.g., to aid in disbursement.
• Propellants can be liquefied gases, including halocarbons, for example, fluorocarbons such as fluorinated chlorinated hydrocarbons, hydrochlorofluorocarbons, and hydrochlorocarbons, as well as hydrocarbons and hydrocarbon ethers.
• fluorocarbons such as fluorinated chlorinated hydrocarbons, hydrochlorofluorocarbons, and hydrochlorocarbons, as well as hydrocarbons and hydrocarbon ethers.
• Halocarbon propellants useful in the present invention include fluorocarbon propellants in which all hydrogens are replaced with fluorine, chlorofluorocarbon propellants in which all hydrogens are replaced with chlorine and at least one fluorine, hydrogen-containing fluorocarbon propellants, and hydrogen-containing chlorofluorocarbon propellants.
• Halocarbon propellants are described in Johnson, U.S. Pat. No. 5,376,359, issued Dec. 27, 1994; Byron et al, U.S. Pat. No. 5,190,029, issued Mar. 2, 1993; and Purewal et al., U.S. Pat. No. 5,776,434, issued JuL 7, 1998.
• Hydrocarbon propellants useful in the invention include, for example, propane, isobutane, n-butane, pentane, isopentane and neopentane.
• a blend of hydrocarbons can also be used as a propellant.
• Ether propellants include, for example, dimethyl ether as well as the ethers.
• An aerosol formulation of the invention can also comprise more than one propellant.
• the aerosol formulation can comprise more than one propellant from the same class, such as two or more fluorocarbons; or more than one, more than two, more than three propellants from different classes, such as a fluorohydrocarbon and a hydrocarbon.
• compositions of the present invention can also be dispensed with a compressed gas, e.g., an inert gas such as carbon dioxide, nitrous oxide or nitrogen.
• a compressed gas e.g., an inert gas such as carbon dioxide, nitrous oxide or nitrogen.
• Aerosol formulations can also include other components, for example, ethanol, isopropanol, propylene glycol, as well as surfactants or other components such as oils and detergents. These components can serve to stabilize the formulation and/or lubricate valve components.
• the aerosol formulation can be packaged under pressure and can be formulated as an aerosol using solutions, suspensions, emulsions, powders and semisolid preparations.
• a solution aerosol formulation can comprise a solution of a compound of the invention such as a novel HMG-CoA reductase inhibitor in (substantially) pure propellant or as a mixture of propellant and solvent.
• the solvent can be used to dissolve the compound and/or retard the evaporation of the propellant.
• Solvents useful in the invention include, for example, water, ethanol and glycols. Any combination of suitable solvents can be use, optionally combined with preservatives, antioxidants, and/or other aerosol components.
• An aerosol formulation can also be a dispersion or suspension.
• a suspension aerosol formulation may comprise a suspension of a compound or combination of compounds of the instant invention, e.g., an HMG CoA reductase inhibitor, and a dispersing agent. Dispersing agents useful in the invention include, for example, sorbitan trioleate, oleyl alcohol, oleic acid, lecithin and corn oil.
• a suspension aerosol formulation can also include lubricants, preservatives, antioxidant, and/or other aerosol components.
• An aerosol formulation can similarly be formulated as an emulsion.
• An emulsion aerosol formulation can include, for example, an alcohol such as ethanol, a surfactant, water and a propellant, as well as a compound or combination of compounds of the invention, e.g., an HMG-CoA reductase inhibitor.
• the surfactant used can be nonionic, anionic or cationic.
• One example of an emulsion aerosol formulation comprises, for example, ethanol, surfactant, water and propellant.
• Another example of an emulsion aerosol forumalation comprises, for example, vegetable oil, glyceryl monostearate and propane.
• Example 4v describes a dry powder aerosol formulation comprising pitavastatin lactone and lactose.
• Example 4w describes a dry powder aerosol formulation comprising fluvastatin sodium.
• Example 4x describes a dry powder aerosol formulation comprising atorvastatin lactone.
• Example 4y describes a metered-dose aerosol formulation comprising atorvastatin lactone.
• compositions suitable for use in the present invention include compositions wherein the active ingredients are present in an effective amount, i.e., in an amount effective to achieve therapeutic and/or prophylactic benefit in at least one of a MAP kinase-related condition and an HMG-CoA reductase-related condition.
• an effective amount i.e., in an amount effective to achieve therapeutic and/or prophylactic benefit in at least one of a MAP kinase-related condition and an HMG-CoA reductase-related condition.
• the actual amount effective for a particular application will depend on the condition or conditions being treated, the condition of the subject, the formulation, and the route of administration, as well as other factors known to those of skill in the art. Determination of an effective amount of a MAP kinase and/or HMG-CoA reductase inhibitor is well within the capabilities of those skilled in the art, in light of the disclosure herein, and will be determined using routine optimization techniques.
• the effective amount for use in humans can be determined from animal models. For example, a dose for humans can be formulated to achieve circulating, liver, topical and/or gastrointestinal concentrations that have been found to be effective in animals.
• a dose for humans can be formulated to achieve circulating, liver, topical and/or gastrointestinal concentrations that have been found to be effective in animals.
• One skilled in the art can determine the effective amount for human use, especially in light of the animal model experimental data described herein.
• Example 8 provided below, details an experiment where an inflammatory condition was induced in mice, compositions of the present invention were administered, and anti-inflammatory effect obsereved.
• Table II shows the resulting percentage of inhibition and effective amounts of compounds and combinations of compounds of the instant invention. Based on this animal data, and other types of similar data, those skilled in the art can determine the effective amounts of compositions of the present invention appropriate for humans.
• the effective amount when referring to a compound or combination of compounds of the invention will generally mean the dose ranges, modes of administration, formulations, etc., that have been recommended or approved by any of the various regulatory or advisory organizations in the medical or pharmaceutical arts (e.g., FDA, AMA) or by the manufacturer or supplier.
• Effective amounts of HMG-CoA reductase inhibitors can be found, for example, in the Physicians Desk Reference.
• daily doses for atorvastatin calcium range from about 2 mg to about 50 mg, from about 3 mg to about 30 mg, typically about 10 mg.
• a daily dose for cerivastatin sodium is about 200 [Ig, while daily doses for fluvastatin sodium, rosuvastatin sodium, pravastatin sodium and simvastatin are each about 20 mg.
• Some preferred compounds of this invention e.g., analogs of HMG-CoA reductase inhibitors, maybe useful in about the same dosages, or less than or more than dosages typical of known HMG-CoA reductase inhibitors.
• MAP kinase inhibitors can be found, for example, in published reports of the results of human clinical trials.
• the recommended dosage for a MAP kinase inhibitor of the present invention is a dose of about 0.01mg/kg to about 1,000 mg/kg, more preferably from about 0.1 mg/kg to about 20 mg/kg on a daily basis, provided orally.
• the inhibitor is typically administered in a dose of about 100 mg, which is in the range of doses that will be useful in the present invention.
• a dose of about 0.01 mg/kg/day to about 1,000 mg/kg/day of a MAP kinase inhibitor will be used; preferably a dose between about 0.1 mg/kg/day and about 20 mg/kg/day will be used.
• the recommended dosage for an HMG-CoA reductase inhibitor of the present invention is a dose of about 0.01mg/kg to about 1,000 mg/kg, more preferably from about 0.1 mg/kg to about 20 mg/kg on a daily basis, provided orally.
• the inhibitor is typically administered in a dose of about 10 mg, which is in the range of doses that will be useful in the present invention.
• a dose of about 0.01 mg/kg/day to about 1,000 mg/kg/day of an HMG-CoA reductase inhibitor will be used; preferably a dose between about 0.1 mg/kg/day and about 1 mg/kg/day will be used.
• statin lactone hydroxy acid form of a statin or non-statin anti-inflammatory agent
• in vitro potency of a compound in inhibiting HMG-CoA reductase and/or inhibiting inflammation mediators provides information useful in the development of effective in vivo dosages to achieve similar biological effects.
• Effective amounts of compounds and/or combinations of compounds of the instant invention for use in increasing HDL levels can similarly be determined based on in vitro experimental data, including animal model data.
• an animal model can be used to determine a percentage increase in HDL levels that would be desirable in humans, and corresponding effective doses of the com ⁇ ound(s) or combinations of compounds to achive such levels.
• administration of compounds of the present invention may be intermittent, for example administration once every two days, every three days, every five days, once a week, once or twice a month, and the like, m some embodiments, the amount, forms, and/or amounts of the different forms may be varied at different times of administration. For example, at one point in time, the acid form of a compound of the present invention may be administered, while at another time the corresponding lactone form may be used.
• a person of skill in the art would be able to monitor in a patient the effect of administration of a particular compound. For example, cholesterol levels can be determined by measuring LDL, HDL, and/or total serum cholesterol levels.
• the release of pro-inflammatory cytokines can be determined by measuring TNF- ⁇ and/or IL-I ⁇ . Other techniques would be apparent to one of skill in the art. IV. Rational Design of Kinase and/or HMG-CoA Reductase Inhibitors
• Still another aspect of the present invention relates to methods of obtaining and/or making a composition for inhibiting a MAP kinase and/or HMG CoA reductase by designing a compound of formula I/II/III/IV; testing whether the compound inhibits a MAP kinase and/or HMG CoA reductase; and using the compound in making a composition for inhibiting a MAP kinase and/or HMG-CoA reductase. More preferably, the invention relates to methods for designing and testing compounds of formula I/II that are capable of inhibiting both MAP kinase and HMG-CoA reductase.
• formula I/II it is meant that either the ⁇ -lactone or the hydroxy carboxylic acid forms, or both forms, may be responsible for inhibition of a MAP kinase, HMG-CoA reductase or both.
• Figure 11 illustrates a design approach for developing compounds that inhibit a MAP kinase and/or HMG-CoA reductase.
• Figure 11a illustrates an approach in which known inhibitors of MAP kinases are systematically varied and tested for HMG-CoA reductase inhibitory activity.
• known inhibitors of MAP kinases and analogs thereof are appended or substituted with an A- ⁇ -lactone or an A-hydroxy carboxylic acid group of formulas I or II, respectively.
• the lipophilic moiety (X) is a known MAP kinase inhibitor or a lipophilic moiety thereof.
• Figure 4 illustrates known p38 ⁇ MAP kinase inhibitors that may be used in designing some preferred embodiments.
• the lipophilic moiety is an analog of a MAP kinase inhibitor, for example, selected on the basis of structural diversity or similarity to an HMG-CoA reductase inhibitor, preferably to a lipophilic moiety of an HMG-CoA reductase inhibitor, or on the basis of structural compatibility with binding to HMG-CoA reductase, for example, using pharmacophore modeling to indicate binding compatibility.
• Figure 5 illustrates MAP kinase analogs preferred in some embodiments.
• Figure 1 Ib illustrates an approach in which known inhibitors of HMG-CoA reductase are systematically varied and tested for MAP kinase inhibitory activity.
• lipophilic moieties (X) of known inhibitors of HMG-CoA reductase are systematically varied, resulting in analogs.
• the lipophilic moiety analog is selected on the basis of structural diversity or similarity to a MAP kinase inhibitor, preferably to a lipophilic moiety of a MAP kinase inhibitor, on the basis of structural compatibility with binding to a MAP kinase, such as p38 ⁇ MAP kinase, for example, using pharmacophore modeling to indicate binding compatibility.
• Figure 7 illustrates preferred lipophilic moiety analogs
• Figure 8 illustrates specific examples of statin analogs, which are even more preferred in some embodiments.
• the rational design methods of the present invention are aided by the current understanding of the crystal structures of HMG-CoA reductase and MAP kinases.
• the X- ray structure of p38ce MAP kinase for example, has been shown to comprise an N- terminal domain with an ATP binding pocket, and a C-terminal domain with a catalytic site, metal binding site, and phophorylation lip. The two domains are connected by a hinge region, to which the substrate binds. Further, a direct correlation has been shown between the "tightness" of binding of a candidate compound to the enzyme and the in vitro cellular activity of the compound.
• Figure lie illustrates an approach in which the lipophilic moiety of compounds of formula I or II is varied and tested for MAP kinase and/or HMG-CoA reductase inhibitory activity.
• the lipophilic moiety is randomly selected, hi some embodiments, the lipophilic moiety is selected on the basis of structural diversity or similarity to a MAP kinase inhibitor or on the basis of structural compatibility with binding to a MAP kinase, for example, using pharmacophore modeling to indicate binding compatibility, hi some embodiments, the lipophilic moiety is selected on the basis of structural diversity or similarity to an HMG-CoA reductase inhibitor or on the basis of structural compatibility with binding to an HMG-CoA reductase, for example, using pharmacophore modeling to indicate binding compatibility.
• Selected lipophilic moieties can be appended with an A- ⁇ -lactone or an A-hydroxy carboxylic acid group of formulas I or II, respectively, and then tested for inhibition of a MAP kinase and/or inhibition of an HMG-CoA reductase.
• Tests involves evaluation of the designed compounds for inhibitory activity towards a MAP kinase and/or HMG-CoA reductase, hi some embodiments, the collection of designed analogs may be evaluated by computational methods to predict their activity in inhibiting a MAP kinase and/or HMG-CoA reductase, without physically synthesizing the compounds. Such computational methods may also be used to predict other properties of the compounds, such as solubility, membrane penetrability, metabolism and toxicity.
• testing involves synthesizing the designed compounds and evaluating their activity in inhibiting a MAP kinase and/or HMG-CoA reductase in one or more biological assays via wet lab techniques.
• Known methods for the synthesis of inhibitors of HMG-CoA reductase and MAP kinases can be adapted to prepare the designed analogs in either the ⁇ -lactone or the hydroxy carboxylic acid form, as well as in carboxylate (salt) form.
• the activity of the synthesized compound can then be evaluated by a biological assay, which directly or indirectly reflects the inhibition of a MAP kinase, and/or the inhibition of HMG-CoA reductase.
• Representative biological assays include, but are not limited to, 1) cell-free studies of MAP kinase inhibition; 2) cell-free studies of HMG-CoA reductase inhibition; 3) whole-cell studies of inhibition of inflammatory responses (such as cytokine production and/or release upon challenge by agents, including lipopolysaccharide (LPS)); 4) whole cell studies of terpene and sterol biosynthesis; 5) in vivo models of efficacy against MAP kinase-related conditions, such as inflammatory and/or autoimmune conditions, including arthritis, rheumatoid arthritis, osteoarthritis, vascular inflammatory conditions, inflammatory bowel disease, psoriasis, topical dermatitis, eczema, endotoxemia, sepsis, and toxic shock syndrome, as well as transplant rejection; 6) in vivo models of efficacy in treating HMG-CoA reductase-related conditions, such as hypercholesterolemia, lipid disorders such as
• the ability of a candidate compound to inhibit MAP kinase and/or HMG-CoA reductase activity can be evaluated by contacting the compound with an assay mixture for measuring activity of a MAP kinase and/or HMG- CoA reductase, and determining the activity of the enzyme in the presence and absence of the compound.
• a decrease in activity of a MAP kinase in the presence as opposed to the absence of the compound indicates a MAP kinase inhibitor.
• a decrease in the activity of HMG-CoA reductase in the presence as opposed to the absence of the compound indicates an HMG-CoA reductase inhibitor.
• MAP kinase and HMG-CoA reductase are known and commercially available, facilitating simple in vitro assays for inhibitory activity.
• An example of a cell-free MAP kinase assay involves that described in Clerk and Sugden, FEBS Letters, 426:93-96 (1998), incorporated herein by reference. Briefly, serum can be withdrawn from neonatal rats and myocytes exposed to sorbitol (about 30 min) in the absence or presence of about 10 ⁇ M or less of a candidate compound.
• SAPKs/JNKs can be separated by FPLC on a Mono Q HR5/5 column where the MAP kinases are eluted using about a 30 ml linear NaCl gradient (about 0 to about 0.5 M NaCl). They can be assayed by the direct method with myelin basic protein (MBP) or about 0.5 mg/ml glutathione S-transferase-GST-c-Jun(l-135) as substrate, where the assay mix contains about 0.1% (v/v) dimethyl sulphoxide or about 10 ⁇ M of a candidate compound (final concentrations). Samples of fractions can be taken for in-gel kinase assays.
• MBP myelin basic protein
• S-transferase-GST-c-Jun(l-135) as substrate
• the assay mix contains about 0.1% (v/v) dimethyl sulphoxide or about 10 ⁇ M of a candidate compound (final concentrations).
• Fractions may be pooled and concentrated by ultra-filtration and prepared for immunoblot analysis.
• proteins can be applied to a Mono S HR5/5 column and MAP-KAPK2 purified and assayed.
• GST-c-Jun(l-135) can be used to "pull down" total SAPKs/JNKs from myocyte extracts.
• Pellets can be washed in kinase assay buffer (for example, about 20 niM HEPES pH about 7.7, about 2.5 mM MgCl 2 , about 0.1 mM EDTA, about 20 mM ⁇ -glycerophosphate) containing the final concentrations of a candidate compound.
• kinase assay buffer for example, about 20 niM HEPES pH about 7.7, about 2.5 mM MgCl 2 , about 0.1 mM EDTA, about 20 mM ⁇ -glycerophosphate
• the pellets can be re-suspended in about 15 ⁇ l kinase assay buffer containing twice the final concentrations of a candidate compound and phosphorylation can be initiated with about 15 ⁇ l of kinase assay buffer containing about 10 ⁇ M ATP and about 1 ⁇ Ci [ ⁇ - P]ATP. JNKl isoforms can be immunoprecipitated from myocyte extracts using antibodies. The pellets can be washed in kinase assay buffer containing the final concentrations of a candidate compound.
• Example 5 provides further details of a human p38 ⁇ MAP kinase inhibition assay, as results using a number of candidate compounds.
• HMG-CoA reductase assay involves radiometric procedures described in Shum et al., Ther. DrugMonit. 20:41-49 (1998), incorporated herein by reference. Briefly, about 150 ⁇ g/mL of HMG-CoA reductase can be incubated with a candidate compound, together with about 12 ⁇ M [ 14 C]HMG-CoA and about 200 ⁇ M NADPH in about 200 ⁇ L 0.2M phosphate buffer (pH about 7.2) for about 0.5 h at about 37 0 C.
• the [ 14 C]mevalonate that forms can be converted under acidic conditions to [ 14 C]mevalonolactone and separated from un-reacted substrate, for example, by ion- exchange chromatography, and then quantified, for example, by liquid scintillation counting.
• An example of a whole cell assay of inhibition of inflammatory responses involves evaluating murine thymic T cell proliferation and TL-2 production or gene expression in the presence and absence of a candidate compound. Methods for measuring T cell proliferation and IL-2 production are standard, well known techniques in the art. Other examples of whole cell assays for inflammation are also known in the art, for example, as described in Welker et al., Int. Arch. Allergy & Immunology, 109:110-115 (1996); Suhindler et al., Blood, 75:40 (1990); and Gulenboik et al., JBL, 266:19490 (1991), incorporated herein by reference.
• Example 6 provided below, further details a whole-cell anti-inflammation assay useful in certain rational design embodiments of the present invention.
• Example 7 provided below, further details a whole-cell LPS- stimulated TNF- ⁇ release assay also useful in certain rational design embodiments of the present invention.
• Animal models used to reflect inflammatory or immune responses can be utilized to evaluate MAP kinase inhibitory activity in vivo.
• Exemplary animal models include, but are not limited to, release of inflammatory mediators in response to LPS administration to mice or rats; the mouse acute irritant model; inbred NC/Nga mice, which develop chronic relapsing skin inflammation when reared under non-pathogen-free conditions; Balb/c mice, which develop dermatitis when injected with Shistosoma japonica glutathione-S-transferase; mice sensitized by repetitive epicutaneous exposure to ovalbumin antigen that model atopic dermatitis; and dextran sulfate sodium, trinitrobenzene sulfonic acid, and oxazolone-induced colitis, which model inflammatory bowel disease.
• Example 8 provides more details of a topical inflammation animal model useful in certain rational design embodiments of the present invention.
• the activity or potency of a compound of formula I/II is similar towards a MAP kinase and HMG-CoA reductase, preferably as measured by whole cell and/or in vivo assays of IC50 or ED50 values, as described in more detail above, hi preferred embodiments, potencies with respect to a MAP kinase and HMG-CoA reductase differ by no more than a factor of about 1000. More preferably, potencies differ by no more than a factor of about 100. Most preferably, potencies differ by no more than a factor of about 10.
• the lactone form of a compound is the more potent form against a MAP kinase
• the hydroxy carboxylic acid form or carboxylate (salt) form is the more potent form against HMG-CoA reductase
• the potencies of these forms against their respective targets differs by no more than a factor of about 10.
• the potency of a compound of formula I/II against a MAP kinase is greater than its potency against HMG-CoA reductase, m such embodiments, potencies with respect to a MAP kinase and HMG-CoA reductase differ by at least a factor of about 10. More preferably, potencies differ by more than a factor of about 100. Most preferably, potencies differ by more than a factor of about 1000. [00325] In yet other preferred embodiments, the potency of a compound of formula I/II against HMG-CoA reductase is greater than its potency against a MAP kinase.
• potencies with respect to HMG-CoA reductase and a MAP kinase differ by at least a factor of about 10. More preferably, potencies differ by more than a factor of about 100. Most preferably, potencies differ by more than a factor of about 1000.
• Example 1 Synthesis of Atorvastatin Lactone. 5.0 g (8.6 mmole) of atorvastatin calcium was dissolved in 300 mL ethyl acetate and washed with 300 mL 10% (w/v) aqueous sodium hydrogen sulfate solution (pH 3). The organic phase was dried over anhydrous magnesium sulfate, filtered and the solvent removed under reduced pressure to afford 2.85 g (5.11 mmole) of atorvastatin acid.
• Example 2 Synthesis of Fluvastatin Lactone. 7.0 g (16 mmole) of fluvastatin sodium was dissolved in 300 rnL ethyl acetate and washed with 300 mL 10% (w/v) aqueous sodium hydrogen sulfate solution (pH 3). The organic phase was dried over anhydrous magnesium sulfate, filtered and the solvent removed under reduced pressure to afford 5.76 g (14.0 mmole) of fluvastatin acid.
• Example 3 Synthesis of Simvastatin Sodium. 1.43 g (3.42 mmole) of simvastatin lactone was dissolved in 10 mL acetonitrile and treated with water (5 mL) and sodium hydroxide (151 mg, 3.78 mmole). The reaction was stirred at room temperature for 3 days, at which time analytical thin-layer chromatography using 4:1 methylene chloride: acetone eluent indicated essentially complete conversion of the starting lactone to a more polar product.
• reaction mixture was then diluted to 50 mL with 1 : 1 acetonitrile: water, frozen and lyophilized to afford 1.22 g (2.66 mmole, 77.8%) of simvastatin sodium as a fluffy white solid.
• the 400 MHz 1 H nuclear magnetic resonance (NMR) spectrum was consistent with the sodium carboxylate product.
• Example 4 Pharmaceutical Compositions Comprising a Compound(s) of Formula I/IIa/IIb or III or IV, optionally with a Known Anti-Inflammatory Agent(s), for Local/Regional Applications.
• Example 4b Coated tablets
• Example 4c Coated tablets of enteric-coated granules
• Atorvastatin lactone 1.0 g
• Example 4e Polyethylene Glyc
• Atorvastatin lactone 1.0 g
• Atorvastatin lactone 0.10 g
• Example 4g Ointment in Hydrophilic Petrolatum USP. Atorvastatin lactone 1.5 g
• Example 4i Cream formulation
• Example 4j Atorvastatin lactone skin ointment in Petrolatum USP Ointment.
• Example 4m Pitavastatin lactone skin ointment in Polyethylene Glycol Ointment NF. Pitavastatin lactone 2.0 g
• Example 4n Isotonic rosuvastatin calcium solution for ocular use. Rosuvastatin calcium LO g
• Example 4o Cerivastatin lactone ointment for ocular use.
• Example 4p Ointment for ocular use.
• Atorvastatin lactone 1.0 g
• Example 4r Cerivastatin sodium r
• Example 4s Pitavastatin lactone retention enema.
• Example 4t Fluvastatin lactone rectal suppository.
• Example 4u Atorvastatin lactone rectal suppository.
• Atorvastatin lactone 0.10 g
• the mixture is micronized to mass median particle size between 3 - 6 ⁇ m
• Example 4w Fluvastatin sodium metered-dose aerosol formulation Fluvastatin sodium 0.080 g
• Atorvastatin lactone 0.004 g
• Atorvastatin lactone 0.040 g
• Example 5 Human p38 ⁇ MAP Kinase Inhibition Assay.
• Candidate compound and/or vehicle was preincubated with 0.075 ⁇ g/mL enzyme in modified HEPES buffer pH 7.4 at 25°C for 15 minutes. The reaction was initiated by addition of 100 ⁇ M ATP and allowed to proceed for another 60 minutes. The reaction was terminated by aspirating the solution. Phosphorylated MBP was detected by incubation with a mouse monoclonal IgG2a anti-phosphoMBP antibody. Bound anti- phosphoMBP antibody was quantitated by incubation with a HRP conjugated goat anti- mouse IgG. The protein kinase activity was proportional to the readings of optical density at 405 nm resulting from reaction with an ABTS Microwell Peroxidase Substrate System.
• Example 6 Whole Cell Anti-Inflammation Assay.
• PBMCs can be prepared from four different donors by differential centrifugation on Ficoll-Hypaque (Seromed, Berlin, Germany). Two donors (1 and 2) may have seasonal rhino-conjunctivitis, e.g., with positive prick tests to inhalant allergens and elevated serum IgE levels. PBMCs may contain approximately 10% CD14-positive monocytic cells, approximately 90% lymphocytes and approximately ⁇ 1 % granulocytes and platelets.
• THP-I cells are obtained from the ATCC (Rockville, Md., USA; TIB 202) and can be routinely kept in RPMI medium (Gibco, Eggenstein, Germany) with 10% FCS (Seromed) and 50 ⁇ Mmercaptoethanol (Gibco) added.
• HL-60 cells ATCC; No. CCL 240
• U-937 cells ATCC; No. CCL 1593
• FCS Chloros
• glucocorticoids are dissolved in DMSO: Methylprednisolone aceponate (MPA), methylprednisolone- 17-propionate (MPP), prednicarbate (PC) and betamethasone valerate (BMV) (Schering, Berlin, Germany).
• MPA Methylprednisolone aceponate
• MPP methylprednisolone- 17-propionate
• PC prednicarbate
• BMV betamethasone valerate
• All cells (10 6 /ml) can be kept in 24-well polystyrene culture plates and stimulated with lipopolysacharide (LPS; 50 ng/ml; Sigma, St. Louis, Mo., USA) for 24 h at 37°C in RPMI medium (Gibco) without serum, alone or with 10 '5 - '8 MGC added.
• LPS lipopolysacharide
• THP-I , HL-60 and U-937 cells can also be stimulated with a combination of phorbol myristate acetate (PMA; 25 ng/ml) and the calcium ionophore A23187 (Ion; 2x ⁇ 7 M; both from Sigma), hi pre-incubation experiments, cells are cultured for 1 h with the different GCs (10 "6 M) before addition of the stimulus. As controls, cells are cultured with medium only, without stimulus or GCs and with 0.1% DMSO. After incubation, cells are centrifuged, and the culture supernatants frozen at -2O 0 C until analysis.
• PMA phorbol myristate acetate
• Ion calcium ionophore A23187
• Cytokines (IL-l ⁇ , 1L-8 and TNF- ⁇ ) in cell supernatants can be quantified by ELISA (Quantikine, Biermann, Bad Nauheim, Germany), and data can be expressed as means of two values calculated for 10 6 viable cells. Data of duplicate measurements may fluctuate within a very narrow margin ( ⁇ 5%). All experiments can be repeated three (cell lines) or four (PBMC) times. 5x10 7 THP-I cells stimulated for 24 h with or without PMA/A23187 and with or without 10 '6 M MPA can be lysed with 3 M lithium chloride and 6 M urea, centrifuged at 20,000 rpm for 60 min, and RNA extracted in phenol- chloroform.
• RNA per lane can be electrophorased and transferred to nitrocellulose membranes (NEN Research, Boston, Mass., USA) by standard techniques.
• HinIII/Bam- ⁇ I DNA fragments of TNF- ⁇ (680 bp) can be used. The fragments can be nick translated using 32 P -labeled dCTP (NEN Research) and a random primer labeling kit (Boehringer, Mannheim, Germany).
• Hybridization can be carried out in SSC (NaCl/sodium citrate) (Sigma) buffer containing 50% formamide (Sigma) and 10% dextran sulfate (Sigma) over-night at 42 0 C, according to standard procedures.
• nitrocellulose membranes can be washed twice in 2xSSC buffer containing 0.1% sodium dodecyl sulfate (SDS; Sigma) for 15 min at 42°C and twice in 0.2 x SSC containing 0.1 SDS at 5O 0 C. After drying, the blot can be exposed to an X-ray film (Kodak, Rochester, Mass., USA) for up to 7 days.
• SDS sodium dodecyl sulfate
• IC 50 data (inhibitory constants) may be calculated as the GC concentration that cause 50% inhibition of cytokine release, using a computer-assisted program (SPSS, Microsoft).
• Example 7 Whole Cell LPS-Stimulated TNF- ⁇ Release Assay
• PBML peripheral blood mononuclear leukocytes
• LPS lipolysaccharide
• TNF- ⁇ cytokine levels in the conditioned medium can then be quantitated using a sandwich ELISA kit.
• Example 8 Model for Inhibition of Topical Inflammation.
• Groups of 5 BALB/c male mice weighing 22 + 2 g were sensitized by application of oxazolone (100 ⁇ L, 1.5% v/v in acetone) to the shaved abdominal surface.
• oxazolone 100 ⁇ L, 1.5% v/v in acetone
• vehicle alone 20 ⁇ L
• Table II shows a 50%, 58% or 40% inhibition of inflammatory ear swelling upon admininstration of atorvastatin lactone at a dose of 2 x 0.3 mg, while the administration of the non-statin anti-inflammatory agent indomethacin showed a 44% inhibition.
• Table II also shows 64% inhibition of inflammation where the treatment comprised administration of atorvastatin lactone and indomethacin. The 64% inhibition is an example of a synergistic effect by the combination of the statin lactone and the non- statin anti-inflammatory agent.
• atorvastatin lactone exhibits the most potent anti-inflammatory activity in this assay, with 40% inhibition of ear swelling at a dose of 2 x 0.3 mg.
• atorvastatin lactone displays similar potency to the non-steroidal anti-inflammatory drug indomethacin.
• a combination of atorvastatin lactone and indomethacin is more effective at reducing ear swelling than either agent alone.
• atorvastatin sodium and pravastatin calcium effectively inhibit ear swelling by 63% and 60%, respectively, at a dose of 2 x 2 mg.
• step 1 the structure indicated below is used in attaching the side chain and is prepared in eight steps (steps 1 -8)
• Step 1 ethyl 5-hydroxy-3-oxo-7-(trimethylsilyl)hept-6-ynoate, 1, is prepared as follows:
• the cooling bath is removed and the mixture left to warm for 1 h, then re-cooled to -78 0 C and the aldehyde (103.0 g) is added neat, dropwise.
• the mixture is partitioned between ethyl acetate and water, acidifying the aqueous layer to pH 2.
• the aqueous layer is extracted with further portions of ethyl acetate and the combined organics washed with brine twice, dried over magnesium sulfate, filtered, and concentrated to a brown oil (266 g) which is used crude in the next step.
• Step 2 ethyl 3,5-dihydroxy-7-(trimethylsilyl)hept-6-ynoate, 2, is prepared as follows:
• the compound obtained in this step shows the following NMR data: 1 H-NMR (270MHz, CDCl 3 , ⁇ ) 0.17(s, 9H), 1.26(t, 3H), 1.82-1.96(m, 2H), 3.06(brs, IH), 3.58(brs, IH), 4.17(q, 2H), 4.21-4.29(m, IH), 4.60-4.67(dd, IH).
• Step 3 ethyl 2-(2,2-dimethyl-6-((trimethylsilyl)ethynyl)- 1,3 -dioxan-4- yl)acetate, 3, is prepared as follows:
• the compound obtained in this step shows the following NMR data: 1 H-NMR (270MHz, CDCl 3 , ⁇ ) 0.17(s, 9H), 1.26(t, 3H), 1.43(s, 3H), 1.48(s, 3H), 1.52°1.89(m, 2H), 2.35-2.62(m, 2H), 4.16(q, 2H), 4.22-4.37(m, IH), 4.70(dd, IH).
• Step 4 2-(6-ethynyl-2,2-dimethyl-l,3-dioxan-4-yl)acetic acid, 4, is prepared as follows:
• the compound obtained in this step shows the following NMR data: 1 H-NMR (270MHz, CDCl 3 , ⁇ ) 1.43(s, 3H), 1.47(s, 3H), 1.61-1.95(m, 2H), 2.45-2.65(m, 3H), 4.23- 4.40(m, IH), 4.68-4.72(m, IH).
• Step 5 (i?)-l-(naphthalen-l-yl)ethanaminium, (4R, 6S)- and (4S, 6R)-2-(6- ethynyl-2,2-dimethyl-l,3-dioxan-4-yl)acetate salt, 5, is prepared as follows:
• Step 6 (i?)-l-(naphthalen-l-yl)ethanammium, 2-((4i ⁇ 6»S)-6-ethynyl-2,2- dimethyl-l,3-dioxan-4-yl)acetate salt, 6, is prepared as follows:
• the compound obtained in this step shows the following NMR data: 1 H-NMR (270MHz, CDCl 3 , ⁇ ) 1.30(s, 3H), 1.32(s, 3H), 1.63 (d, 3H), 1.24-1.71(m, 2H), 2.07(ddd, 2H), 2.45(s, IH), 3.95-4.05(m, IH), 4.48(m, IH), 5.03-5.13(q, IH), 6.20-6.65(brs, 3H), 7.48-7.62(m, 3H), 7.66(d, IH), 7.79(d, IH), 7.88(d, IH), 8.03(d, IH).
• Step 7 2-((4i?,65)-6-ethynyl-2,2-dimethyl-l,3-dioxan-4-yl)acetic acid, 7, is prepared as follows:
• the compound obtained in this step shows the following NMR data: 1 H-NMR (270MHz, CDCl 3 , ⁇ ) 1.43(s, 3H), 1.47(s, 3H), 1.61-1.95(m, 2H), 2.45-2.65(m, 3H), 4.23- 4.40(m, IH), 4.68-4.72(m, IH).
• Step 8 ethyl 2-((4i?,6iS)-6-ethynyl-2,2-dimethyl-l,3-dioxan-4-yl)acetate, 8, is prepared as follows:
• Step 1 the structure indicated below is used in attaching the side chain.
• This structure can be prepared in one step (Step 1) from the product obtained in Example 9a, as detailed below.
• Step 1 ethyl 2-((4S,6£)-2,2-dimethyl-6-vinyl- 1 ,3 -dioxan-4-yl)acetate, 9, is prepared as follows:
• the compound obtained in this step shows the following NMR data: 1 H-NMR (270MHz, CDCl 3 , ⁇ ) 1.26(t, 3H), 1.43(s, 3H), 1.48(s, 3H), 1.30-1.70(m, 2H), 2.46(ddd, 2H), 4.12-4.19(m, 2H), 4.33-4.41(m, 2H), 5.12(d, IH), 5.28(d, IH), 5.77-5.86(m, IH).
• Example 10 Scheme for synthesis of N-pyridyl pyrazole compounds
• Example 10a Synthesis of an N-pyridyl Pyrazole
• Step 1 l-(4-fluorophenyl)-4-methylhexane-l,3-dione, 10, is prepared as follows:
• Step 2 4-hydrazinylpyridin-2(lH)-one, 11, is prepared as follows:
• Step 3 4-(3-5ec-butyl-5-(4-fluorophenyl)-lH- ⁇ yrazol-l-yl)pyridine-2(lH)- one, 12a and 4-(5-5 r ec-butyl-3-(4-fluorophenyl)-lH-pyrazol-l-yl)pyridme-2(lH)-one, 12b are prepared as follows:
• a solution of 1 -(4-fluorophenyl)-4-methylhexane- 1 ,3-dione, 10 (0.200 g) and 4-hydrazinylpyridin-2(lH)-one, 11 (0.113 g) is dissolved in acetic acid (3 mL) and the mixture heated to 90 0 C for 2 h. On cooling, the solution is quenched with sodium hydrogen carbonate and extracted with ethyl acetate. The aqueous layer is extracted with a further portion of ethyl acetate and the combined organic layer is dried over magnesium sulfate, filtered and concentrated to an oil that crystallizes on standing. The residue is triturated with 9:1 iso-hexanes/ethyl acetate to give 0.145 g of 12a and 12b as a mixture.
• Step 4 4-(5-.sec-butyl-3-(4-fluorophenyl)-lH r - ⁇ yrazol-l-yl)-2-chloropyridine, 13a and 4-(3-i r ec-butyl-5-(4-fluorophenyl)-lH ' -pyrazol-l-yl)-2-chloropyridine, 13b are prepared as follows:
• Flash chromatography affords 2.77 g of 4-(5-5 ⁇ c-butyl-3-(4- fluorophenyl)-lH-pyrazol-l-yl)-2-chloropyridine, 13a and 0.54 g of 4-(3-5ec-butyl-5-(4- fluorophenyl)-lH-pyrazol-l-yl)-2-chloropyridine, 13b as well as 0.57 g of mixed fractions.
• Step 5 4-(4-bromo-5-5ec-butyl-3-(4-fluorophenyl)-lH-pyrazol-l-yl)-2- chloropyridine, 14 is prepared as follows:
• Step 7 Ethyl 2-((4i?,6,S)-6-((E)-2-(5 ⁇ ec-butyl-3-(4-fiuorophenyl)-l-(2- (phenylamino)pyridine-4-yl)-lH-pyrazol-4-yl)vinyl)-2,2-dimethyl-l,3-dioxan-4- yl)acetate, 16 is prepared as follows:
• Step 8 (3i?,5S,E)-ethyl 7-(3-5ec-butyl-5-(4-fluorophenyl)-l-(2- phenylammo)pyridin-4-yl)-l/i-pyrazol-4-yl)-3,5-dihydroxyhept-6-enoate, 17 is prepared as follows:
• reaction mixture is partitioned between ethyl acetate and brine, the organic layer is washed with sodium hydrogen carbonate and brine, dried over magnesium sulfate, filtered and concentrated. Purification by flash chromatography affords 0.270 g of the title compound.
• Step 9 (3i?,5 1 S,E)-7-(3-5ec-butyl-5-(4-fluorophenyl)-l-(2- (phenylamino)pyridin-4-yl)-lH-pyrazol-4-yl)-3,5-dihydroxyliept-6-enoic acid calcium salt, 18 is prepared as follow:
• Step 1 (4R,65,E)-6-(2-(3-5ec-butyl-5-(4-fluorophenyl)-l-(2- (phenylamino)pyridine-4-yl)-lH-pyrazol-4-yl)vinyl)-4-hydroxy-tetrahydropyran-2-one, 19 is prepared as follows:
• Examples 10c and 1Od Syntheses of N-pyridyl Pyrazoles [00458] In two additional specific examples, compounds having the structures indicated below are prepared in two steps (Steps 1-2) from intermediate 17 obtained in Example 10a above.
• Step 1 (3i?,5i?)-ethyl 7-(3-sec-butyl-5-(4-fluorophenyl)-l-(2- (phenylamino)pyridin-4-yl)-lH-pyrazol-4-yl)-3,5-dihydroxyheptanoate, 20 and (4i?,6i?)-6- (2-(3-sec-butyl-5-(4-fluorophenyl)-l-(2-(phenylamino)pyridin-4-yl)-lH-pyrazol-4- yl)ethyl)-4-hydroxy-tetrahydropyran-2-one, 21 is prepared as follows:
• Step 2 (3i?,5i?)-7-(3-sec-butyl-5-(4-fluoro ⁇ henyl)-l-(2-(phenylammo)pyridm- 4-yl)-lH-pyrazol-4-yl)-3,5-dihydroxyheptanoic acid calcium salt, 22 is prepared as follows:
• Example 11 Scheme for synthesis of N-pyrimidinyl pyrazole compounds
• Example 11a Synthesis of an N-pyrimidinyl Pyrazole
• Step 1 3,5-diphenyl-lH-pyrazole, 22 is prepared as follows:
• Step 2 4-(3,5-diphenyl-lH-pyrazol-l-yl)-2-(methylthio)pyrimidine, 23 is prepared as follows:
• Step 3 4-(3,5-diphenyl-lH-pyrazol-l-yl)-2-(methylsulfonyl)pyrimidine, 24 is prepared as follows:
• Step 4 4-(4-bromo-3,5-diphenyl-lH-pyrazol-l-yl)-2- (methylsulfonyl)pyrimidine, 25 is prepared as follows:
• Step 5 4-(4-bromo-3,5-diphenyl-lH-pyrazol-l-yl)-N-phenylpyrimidin-2- amine, 26 is prepared as follows:
• Step 6 ethyl 2-((4i?,6,S)-6-((E)-2-(3,5-diphenyl-l-(2-(phenylamino)pyrimidm- 4-yl)-lH-pyrazol-4-yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl)acetate, 27 is prepared as follows:
• product 27 (0.585 g) is obtained as an off-white powder in the same manner as Example 10a, Step 7 from 4-(4-bromo-3,5-diphenyl-lH-pyrazol-l-yl)-JV- phenylpyrimidin-2-amine, 26 (0.886 g)
• Step 7 (3i?,5S,E)-ethyl 7-(3,5-di ⁇ henyl-l-(2-(phenylamino)pyrimidin-4-yl)- lH-pyrazol-4-yl)-3,5-dihydroxyhept-6-enoate, 28 is prepared as follows:
• Step 8 (3i?,5S,E)-7-(3,5-diphenyl-l-(2-(phenylamino)pyrimidin-4-yl)-lH- pyrazol-4-yl)-3,5-dihydroxyhept-6-enoic acid calcium salt, 29 is prepared as follows: 2+
• Step 1 (4i?,6 ⁇ S, J E)-6-(2-(3,5-diphenyl-l-(2-(phenylamino) ⁇ yrimidm-4-yl)-lH- pyrazol-4-yl)vinyl)-4-hydroxy-tetrahydropyraii-2-one, 30 is prepared as follows:
• Step 1 (3i?,5i?)-ethyl 7-(3,5-diphenyl-l-(2-(phenylamino)pyrimidin-4-yl)-lH- ⁇ yrazol-4-yl)-3,5-dihydroxyheptanoate, 31 and (4i?,6i?)-6-(2-(3,5-diphenyl-l-(2- (phenylamino)pyrimidm-4-yl)-liJ-pyrazol-4-yl)etliyl)-4-hydroxy-tetrahydropyraii-2-one, 32 is prepared as follows:
• Step 2 (3i-,5i?)-7-(3,5-diphenyl-l-(2-(phenylamino)pyrimidin-4-yl)-lH- pyrazol-4-yl)-3,5-dihydroxyheptanoic acid, 33 is prepared as follows:
• Step 1 4-methyl-l-(3-(trifluoromethyl)phenyl)pentane-l,3-dione, 34 is prepared as follows:
• Step 2 4-hydrazinyl-2-(methylthio)pyrimidine, 35 is prepared as follows:
• Step 3 4-(3-isopropyl-5-(3-(trifluoromethyl)phenyl)-lH-pyrazol-l-yl)-2- (methylthio)pyrimidine, 36 is prepared as follows:
• Step 4 4-(3-isopropyl-5-(3-(trifluoromethyl)phenyl)-lH-pyrazol-l-yl)-2- (methylsulfonyl)pyrimidine, 37 is prepared as follows:
• Step 5 4-(4-bromo-3-isopropyl-5-(3-(trifluoromethyl)phenyl)-lH " -pyrazol-l- yl)-2-(methylsulfonyl)pyrimidine, 38 is prepared as follows:
• the compound obtained in this step shows the following NMR data: 1 H-NMR (400MHz, CDCl 3 , ⁇ ) 1.40(d, 6H), 2.51(s, 3H), 3.13-3.22(m, IH), 7.58(d, IH), 7.61- 7.69(m, 2H), 7.76(d, IH), 8.17(d, IH), 8.88(d, IH).
• Step 6 4-(4-bromo-3-isopropyl-5-(3-(trifluoromethyl)phenyl)-lH-pyrazol-l- yl)-2-methoxypyrimidine, 39 is prepared as follows:
• Step 7 ethyl 2-((4 J R,6iS)-6-((E)-2-(3-isopropyl-l-(2-methoxypyrimidin-4-yl)-5- (3-(trifluoromethyl)phenyl)-lH-pyrazol-4-yl)vinyl)-2,2-dimethyl-l,3-dioxan-4-yl)acetate, 40 is prepared as follows:
• Step 8 (3i?,5,S,E)-ethyl 3,5-dihydroxy-7-(3-iso ⁇ ro ⁇ yl-l-(2-methoxypyrimidin- 4-yl)-5-(3-(trifluoromethyl)phenyl)-lH-pyrazol-4-yl)hept-6-enoate, 41 is prepared as follows:
• Step 9 (3i?,5S,E)-3,5-dihydroxy-7-(3-iso ⁇ ro ⁇ yl-l-(2-methoxypyrimidin-4-yl)- 5-(3-(trifluoroinethyl)phenyl)-lH " -pyrazol-4-yl)hept-6-enoic acid calcium salt, 42 is prepared as follows:
• the compound obtained in this step has the following mass spectral and NMR data:
• Step 1 (3i?,5S,E)-3,5-dihydroxy-7-(3-isopropyl-l-(2-methoxypyrimidin-4-yl)- 5-(3-(trifluoromethyl)phenyl)-lH-pyrazol-4-yl)hept-6-enoic acid, 43 is prepared as follows:
• Step 2 (4i?,6iS r ,E)-4-hydroxy-6-(2-(3-isopropyl-l-(2-methoxypyrimidin-4-yl)- 5-(3-(trifluoromethyl)phenyl)-lH " -pyrazol-4-yl)vmyl)-tetrahydropyran-2-one, 44 is prepared as follows:
• Step 1 3-oxo-3-(3-(trifluoromethyl)phenyl)propanal, 45 is prepared as follows:
• Step 2 2-(methylthio)-4-(5-(3-(trifluoromethyl)phenyl)-lJi ' -pyrazol-l- yl)pyrimidine, 46 is prepared as follows;
• the compound obtained in this step shows the following NMR data: 1 H-NMR (270MHz, CDCl 3 , ⁇ ) 1.73(s, 3H), 6.52(d, IH), 7.52-7.55(m, IH), 7.60(d, IH), 7.61- 7.72(m, 3H), 7.80(s, IH), 8.55(d, IH).
• Step 3 2-(methylsulfonyl)-4-(5-(3-(trifluoromethyl)phenyl)-lH-pyrazol-l- yl)pyrimidine, 47 is prepared as follows:
• Step 4 4-(4-bromo-5-(3-(trifluoromethyl) ⁇ henyl)-lH r - ⁇ yrazol-l-yl)-2- (methylsulfonyl)pyrimidine, 48 is prepared as follows:
• Step 5 4-(4-bromo-5-(3-(trifluoromethyl)phenyl)-lH-pyrazol-l-yl)-7V- phenylpyrimidin-2-amine, 49 is prepared as follows:
• Step 6 ethyl 2-((4i?,65)-2,2-dimethyl-6-((E)-2-(l-(2-(phenylamino) ⁇ yrimidin- 4-yl)-5-(3-(trifluoromethyl)phenyl)-lH " -pyrazol-4-yl)vinyl)-l ,3-dioxan-4-yl)acetate, 50 is prepared as follows:
• Step 7 (3R,5S,E)-ethyl 3,5-dihydroxy-7-(l-(2-(phenylamino)pyrimidin-4-yl)- 5-(3-(trifluoromethyl)phenyl)-lH-pyrazol-4-yl)hept-6-enoate, 51 is prepared as follows:
• Step 8 (3i-,5»S,E)-3,5-dihydroxy-7-(l-(2-(plienylamino)pyrimidin-4-yl)-5-(3- (trifluoromethyl)phenyl)-lH-pyrazol-4-yl)hept-6-enoic acid calcium salt, 52 is prepared as follows:
• Aqueous sodium hydroxide solution (0.054 mL of a 1 M solution) is added to a solution of (37.,55,E)-CtIIyI 3,5-dihydroxy-7-(l-(2-(phenylamino)pyrimidin-4-yl)-5-(3- (trifluoromethyl)phenyl)-lH-pyrazol-4-yl)hept-6-enoate, 51 (0.031 g) in ethanol (0.4 mL) and the mixture is stirred at room temperature. After 0.5 h the ethanol is removed in vacuo and the remaining aqueous solution is cooled to 0 °C. Aqueous calcium chloride solution (0.23 mL of a 0.118 M solution) is added and the target molecule is collected by filtration as a solid.
• Example Hh Synthesis of an N-pyrimidinyl Pyrazole using an alternative route to intermediate 46 of Example Hg above.
• Step 1 (E)-3-(dimethylamino)-l-(3-(trifluoromethyl)plienyl)prop-2-en-l-one, 53 is prepared as follows:
• Step 2 2-(methylthio)-4-(5-(3-(trifluoromethyl)phenyl)-l J f- ' -pyrazol-l- yl)pyrimidine, 46 is prepared as follows:
• Step 1 4,4,4-trifluoro-l-(3-(trifluorometliyl)metliyl)butane-l,3-dione, 55 is prepared as follows:
• Step 2 2-(methylthio)-4-(3-(trifluoromethyl)-5-(3-(trifluoromethyl)phenyl)- lH-pyrazol-l-yl)pyrimidine, 56 is prepared as follows:
• Example 12 Scheme for Synthesis of Pyrrole Compounds [00610] An scheme for synthesizing a substituted pyrrole compounds of formula VII of the instant invention is provided below. A compound of structure 65 can be prepared in nine steps (Steps 1-9) as detailed below.
• Step 1 (E)-4-(dimethylamino)-l,l-dimethoxybut-3-en-2-one, 57 is prepared as follows:
• Step 2 4-(dimethoxymethyl)-2-(propylthio)pyrimidine, 58 is prepared as follows:
• Step 3 4-(dimethoxymethyl)-2-(propylsulfonyl)pyrimidine, 59 is prepared as follows:
• Step 4 4-(dimethoxymethyl)-2-methoxypyrimidine, 60 is prepared as follows:
• Step 5 2-methoxypyrimidine-4-carbaldehyde, 61 is prepared as follows:

Landscapes

• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Pain & Pain Management (AREA)
• Rheumatology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Plural Heterocyclic Compounds (AREA)

Applications Claiming Priority (4)

Publications (1)

Family

ID=35451387

Family Applications (1)

Country Status (3)

Families Citing this family (12)

Family Cites Families (2)

• 2005
  • 2005-04-29 WO PCT/US2005/014843 patent/WO2006028524A2/en active Application Filing
  • 2005-04-29 WO PCT/US2005/014833 patent/WO2005115397A2/en active Application Filing
  • 2005-04-29 JP JP2007511020A patent/JP2007535558A/ja not_active Withdrawn
  • 2005-04-29 EP EP05818178A patent/EP1755607A2/en not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events